[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"overweight-or-obesity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:overweight-or-obesity":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,38,0,25,[9,43,74,109,131,155,175,211,232,256,279,300,324,346,386,408,432,454,476,496,516,536,556,576,603],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100620154","phase-3-efficacy-and-safety-of-eloralintide-ly3841136-in-participants-with-osteoarthritis-knee-pain-and-obesity-or-overweight-100620154",false,"NCT07353931","Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight","A Master Protocol for Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Osteoarthritis Knee Pain, and Obesity or Overweight (ENLIGHTEN-4)","ENLIGHTEN-4","Inclusion Criteria:\n\n* Have a body mass index (BMI) of 27 kilograms per square meter (kg\u002Fm²) or higher at screening\n* Have a stable body weight (less than 5% body weight change) for 90 days prior to screening\n* Have tried at least once to lose weight through diet but were unsuccessful\n* Have osteoarthritis of the knee and at least one of the following conditions:\n\n  * Be over 50 years old\n  * Have morning knee stiffness that lasts about 30 minutes\n  * Have a crackling or grinding sound or feeling in the knee\n\nExclusion Criteria:\n\n* Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed greater than 1 year before screening)\n* Have a prior or planned endoscopic procedure and\u002For device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)\n* Have type 1 diabetes, type 2 diabetes, or any other type of diabetes\n* Have an active knee infection\n* Have had within 90 days prior to screening:\n\n  * heart attack\n  * stroke\n  * coronary artery revascularization\n  * unstable angina, or\n  * hospitalization due to congestive heart failure\n* Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure\n* Have taken medications or alternative remedies intended for weight loss within 90 days of screening","ALL","18 Years",{"count":21,"type":22},900,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 75 weeks, including screening.",[28,29],"Osteoarthritis","Overweight or Obesity","RECRUITING","2026-06-19",{"date":33,"type":34},"2026-06-23","ACTUAL",{"date":36,"type":34},"2026-02-09",{"date":38,"type":22},"2028-05",{"name":40,"class":41},"Eli Lilly and Company","INDUSTRY",160,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":18,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100621902","effect-of-the-thrive-ai-health-app-on-lifestyle-behaviors-and-quality-of-life-100621902","NCT07376655","Effect of the Thrive AI Health App on Lifestyle Behaviors and Quality of Life","Inclusion Criteria:\n\n* Be at high risk for chronic disease defined as:\n\nBody mass index (BMI)\\>25\n\nBMI\\\u003C=25 who are prediabetic or have type 2 diabetes\n\n* Aged 40 years or older\n\nExclusion Criteria:\n\n* Unable to walk",true,"40 Years",{"count":52,"type":22},20,[54],"NA","The goals of this randomized trial is to learn:\n\n1. If the Thrive AI Health app will help adults improve their everyday habits (diet, exercise, and sleep).\n2. How often participants will use the Thrive AI Health app to which they will have free access\n\nThe Thrive AI Health app uses artificial intelligence (AI) to give personalized advice. It is designed to help people eat better, exercise more, manage stress, and sleep well.\n\nResearchers will compare changes in diet, exercise and sleep in participants using the app to those participants not using the app.\n\nParticipants will complete study questionnaires and an in-person visit at the beginning and end of the study.",[57,29],"Diabetes Type 2",[59,60,61,62],"Health app","Diet","Exercise","Sleep","2026-06-15",{"date":65,"type":34},"2026-06-17",{"date":67,"type":34},"2026-06-04",{"date":69,"type":22},"2027-04",{"name":71,"class":72},"Yale University","OTHER",1,{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":84,"briefSummary":86,"conditions":87,"keywords":95,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":108},"100642828","phase-2-a-study-of-pf-08653945-and-pf-08653944-in-adults-with-overweight-or-obesity-solis-1-100642828","NCT07575932","A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)","A PHASE 2B, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, DOSE RANGING, DOSE-FINDING, UMBRELLA STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08653945 AND PF-08653944, ALONE OR IN COMBINATION, IN ADULTS WITH OVERWEIGHT OR OBESITY (SOLIS-1)","SOLIS-1","Inclusion Criteria:\n\nEligible participants for this study include:\n\n* adults aged 18 years or older with\n* obesity (BMI of 30.0 kg\u002Fm2 to 50.0 kg\u002Fm2) or with\n* overweight (BMI of 27.0 kg\u002Fm2 to \\\u003C30.0 kg\u002Fm2) who also have at least 1 prespecified weight-related comorbidity (hypertension, dyslipidemia, cardiovascular disease, or obstructive sleep apnea), at the screening visit.\n\nExclusion Criteria:\n\nParticipants who are not eligible include those with diabetes mellitus, a body weight change of \\>5% or use of weight loss medications in the 12 weeks prior to screening, a history of or plan for surgical treatment for obesity, and those who are unable or unwilling to comply with contraceptive requirements or are pregnant or lactating.",{"count":83,"type":22},872,[85],"PHASE2","This study is being done to learn about the safety and effects of the study drugs, PF-08653945 and PF-08653944, when given alone or together for weight loss, compared to a placebo (a dummy drug that has no active ingredient in it).",[88,89,90,29,91,92,93,94],"Overweight","Obesity","Overweight and\u002For Obesity","Overnutrition","Nutrition Disorders","Nutritional and Metabolic Diseases","Body Weight",[91,92,93,94,89,88,96,97,98],"GLP-1RA","Amylin","DACRA","2026-06-09",{"date":101,"type":34},"2026-06-10",{"date":103,"type":34},"2026-05-11",{"date":105,"type":22},"2028-01-05",{"name":107,"class":41},"Pfizer",48,{"id":110,"slug":111,"hasResults":12,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":23,"phases":118,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":130},"100582493","phase-4-a-study-to-investigate-effectiveness-of-tirzepatide-following-initiation-of-ixekizumab-in-participants-with-active-psoriatic-arthritis-and-overweight-or-obesity-in-clinical-practice-together-amplify-psa-100582493","NCT06864026","A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)","A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab in Adult Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice.","Inclusion Criteria:\n\n* Have a diagnosis of active psoriatic arthritis (PsA) as defined by a rheumatologist or other healthcare professional (HCP) experienced in treating PsA.\n* Body Mass Index (BMI) of 30 kilograms per meter squared (kg\u002Fm²) or greater (obesity) or 27 kg\u002Fm2 to \\\u003C30 kg\u002Fm² (overweight) in the presence of at least 1 weight-related comorbid condition (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease).\n* Who have been treated with ixekizumab for approximately 3 months (±1 month) prior to decision to add tirzepatide.\n* Must be able to initiate tirzepatide (Day 0) within 30 days of treatment decision (baseline or screening).\n\nExclusion Criteria:\n\n* Have currently received ixekizumab for more than 4 months or less than 2 months.\n* Had any exposure to tirzepatide or other glucagon-like peptide-1 (GLP-1) receptor agonist (for example, dulaglutide, liraglutide, or semaglutide).\n* Are currently enrolled in any other clinical study.\n* Have a known hypersensitivity to any component of tirzepatide.\n* Have a personal or family history of medullary thyroid cancer.\n* Have multiple endocrine neoplasia type 2.\n* Have type 1 diabetes mellitus.\n* Have a history of chronic or acute pancreatitis at any time before screening.\n* Have a history of proliferative diabetic retinopathy, diabetic maculopathy, or nonproliferative diabetic retinopathy that requires acute treatment.\n* Have a history of ketoacidosis or hyperosmolar state\u002Fcoma.\n* Have a history of severe hypoglycemia unawareness within the 6 months before screening.\n* Have a history of severe gastrointestinal complications, including gastroparesis, gastroesophageal reflux disease, dyspepsia, chronic nausea\u002Fvomiting.",{"count":117,"type":22},200,[119],"PHASE4","The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with active PsA and obesity or overweight with at least 1 weight-related comorbidity.\n\nThe study will last up to 12 months.",[122,29],"Psoriatic Arthritis",{"date":124,"type":34},"2026-06-11",{"date":126,"type":34},"2025-03-06",{"date":128,"type":22},"2027-11",{"name":40,"class":41},55,{"id":132,"slug":133,"hasResults":12,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":49,"sex":18,"minAge":19,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":23,"phases":141,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":154},"100631313","phase-1-a-study-of-multiple-doses-of-orally-administered-ro7795081-in-otherwise-healthy-chinese-adult-participants-with-obesity-or-overweight-100631313","NCT07499050","A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight","An Investigator- and Participant-Blind, Randomized, Placebo-Controlled, Parallel-Group, Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight","Inclusion Criteria:\n\n* Participants who are healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring\n* Participants who are ethnically Chinese and living in mainland China\n* Body mass index (BMI) ≥24 kg\u002Fm\\^2 at screening\n* Agreement to adhere to the contraception requirements\n\nExclusion Criteria:\n\n* Any medical condition or disease that could be expected to progress, recur, or change to such an extent that it could bias the assessment of the clinical or mental status of the participant to a significant degree or put the participant at special risk in the opinion of the Investigator. Such conditions may include clinically significantly impaired endocrine, thyroid, hepatic, respiratory, or renal function for any reason, unstable diabetes mellitus and insulin dependent diabetes mellitus, clinically significant cardiovascular disease, pheochromocytoma, or history of any psychotic mental illness.","65 Years",{"count":140,"type":22},30,[142],"PHASE1","This is an investigator- and participant-blind, randomized, placebo-controlled, parallel-group, Phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of orally administered RO7795081 in otherwise healthy Chinese adult participants with obesity or overweight.",[145,29],"Healthy Volunteers",{"date":147,"type":34},"2026-06-08",{"date":149,"type":34},"2026-03-30",{"date":151,"type":22},"2026-12-29",{"name":153,"class":41},"Hoffmann-La Roche",2,{"id":156,"slug":157,"hasResults":12,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":23,"phases":163,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":173,"locationsCount":174},"100582025","phase-4-a-study-to-investigate-the-effectiveness-of-tirzepatide-ly3298176-following-initiation-of-ixekizumab-ly2439821-in-participants-with-moderate-to-severe-plaque-pso-and-obesity-or-overweight-in-clinical-practice-together-amplify-pso-100582025","NCT06857942","A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)","A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab in Adult Participants With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight in Clinical Practice","Inclusion Criteria:\n\n* Have a diagnosis of moderate-to-severe plaque PsO, as defined by a dermatologist or other experienced clinician treated PsO (for example, allergologist, nurse practitioner or physician assistant)\n* Have body mass index (BMI) of 30 kilograms per meter squared (kg\u002Fm²) or greater (obesity) or 27 kg\u002Fm² to \\\u003C30 kg\u002Fm² (overweight) in the presence of at least 1 weight-related comorbid condition (hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular diseases).\n* Must have initiated treatment with ixekizumab for approximately 3 months (± 1 month) prior to decision to add tirzepatide.\n* Must be able to initiate tirzepatide (Day 0) within 30 days of treatment decision (baseline\u002Fscreening).\n\nExclusion Criteria:\n\n* Have currently received ixekizumab for more than 4 months or less than 2 months.\n* Have had any exposure to tirzepatide or other glucagon-like peptide-1 receptor agonist (GLP-1 RAs), for example, dulaglutide, liraglutide, or semaglutide.\n* Are currently enrolled in any other clinical study.\n\nOther exclusions\n\n* Have a known hypersensitivity to tirzepatide or to any of its component.\n* Have a personal or family history of medullary thyroid cancer.\n* Have multiple endocrine neoplasia type 2.\n* Have type I diabetes mellitus.\n* Have a history of chronic or acute pancreatitis at any time before screening (Visit 1).\n* Have a history of proliferative diabetic retinopathy, diabetic maculopathy, or nonproliferative diabetic retinopathy that requires acute treatment.\n* Have a history of ketoacidosis or hyperosmolar state\u002Fcoma.\n* Have a history of severe hypoglycemia and hypoglycemia unawareness within the 6 months before screening.\n* Have a history of severe gastrointestinal complications, including gastroparesis, gastroesophageal reflux disease, dyspepsia, chronic nausea\u002Fconstipation\u002Fvomiting.",{"count":117,"type":22},[119],"The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity.\n\nThe study will last up to 12 months.",[166,29],"Psoriasis","2026-06-02",{"date":169,"type":34},"2026-06-03",{"date":171,"type":34},"2025-03-19",{"date":38,"type":22},{"name":40,"class":41},40,{"id":176,"slug":177,"hasResults":12,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":49,"sex":182,"minAge":183,"maxAge":184,"enrollmentInfo":185,"targetDuration":4,"studyType":23,"phases":187,"briefSummary":188,"conditions":189,"keywords":194,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":73},"100589347","acute-impact-of-whey-protein-enriched-milk-fat-globule-membrane-supplementation-on-postprandial-markers-of-heart-and-brain-health-100589347","NCT06953232","Acute Impact of Whey Protein-enriched Milk Fat Globule Membrane Supplementation on Postprandial Markers of Heart and Brain Health","Acute Impact of Whey Protein-enriched Milk Fat Globule Membrane Supplementation on Postprandial Markers of Heart and Brain Health in Postmenopausal Women Living With Overweight and at Moderate Risk for Cardiovascular Disease.","Inclusion Criteria:\n\n* Apparently healthy postmenopausal women (not menstruating for 12 or more months)\n* Aged 50 - 75 years\n* BMI: 25 - 40 kg\u002Fm²\n* Moderate CVD risk\n* Recreationally active (\\> 3 x 30 min moderate exercise per week)\n* Understands and is willing and able to comply with all study procedures including eating a high-fat breakfast meal\n* Fluent in written and spoken English\n* Access to, and able to use, the internet\u002Fcomputer\u002Ftablet device\n\nExclusion Criteria:\n\n* Smoking (including vaping)\n* Diagnosed with cardiovascular disease or suffered myocardial infarction \u002Fstroke in the past twelve months\n* Existing or significant past medical history of any medical condition likely to affect the study outcomes e.g., diabetes, digestive, cancer or thyroidal disease, neurological disease (Alzheimer's disease, other form of dementia, mild cognitive impairment), or serious mental illness know to affect cognition (schizophrenia, schizoaffective disorder, bipolar disorder), learning disorders (dyslexia)\n* Early or premature menopause resulting from medical conditions or undergoing surgery\n* Hormone replacement therapy within last 6 months\n* Prescribed medications likely to interfere with study outcomes (including lipid\u002Fcholesterol-lowering medications, including statins; blood thinners, antiplatelets (anticoagulants) such as heparin, etc.; medications for blood pressure; inflammation such as nonsteroidal anti-inflammatory drugs, aspirin, etc.; immune function, or lipid\u002Fcarbohydrate metabolism) or prescribed antibiotics within the last three months\n* Use of antidepressant or anti-anxiety medication if it has changed in the last three months or expected to change within the 3-month study period\n* Taking vitamin, mineral, or fatty acid supplements (e.g., fish oil, calcium) or unwilling stop consuming these for the duration of the study (including sufficient washout period)\n* Working night shifts\n* Inaccessible veins for blood collection via cannulation\n* Unstable weight history (≥3 kg loss or gain in the previous 3 months) or planning or currently on a weight reduction scheme\n* Known allergy or intolerance to study food (including lactose intolerance, dairy, and wheat)\n* Being vegan or any other unusual medical history or diet and lifestyle habits or practices that would preclude volunteers from participating in a dietary intervention or metabolic study\n* Excessive alcohol consumption: \\>21 unit\u002Fwk (i.e., more than 10 and a half pints of beer or 21 small glasses of wine)\n* Currently taking part or have participated in another research study in the last two months (e.g., dietary intervention)","FEMALE","50 Years","75 Years",{"count":186,"type":22},16,[54],"In a single-blind, randomised, placebo-controlled crossover manner, this study aims to assess the impact of a high-fat mixed meal containing a whey protein (WP)-enriched milk fat globule membrane (MFGM) powdered ingredient on markers of heart and brain health in the fed state among middle-to-older-aged, postmenopausal women living with overweight and at moderate risk for cardiovascular disease.\n\nParticipants will attend two \\~8 hour study visits, where they will consume a high-fat meal containing a WP-enriched MFGM powdered ingredient or a placebo WP-based powdered ingredient. Each visit will involve anthropometric measurements and periodic assessments of heart health, including blood pressure and blood vessel stiffness measurements, blood sample collections, as well as computer-based tests measuring mood and cognition (brain function) over a 6-hour postprandial period.",[190,191,29,192,193],"Cardiovascular Diseases","Cognition","Postmenopausal Women","Cardiometabolic Risk Factors",[195,196,197,198,199,200,201],"Milk fat globule membrane","Milk polar lipids","triacylglycerol","postprandial","cholesterol","cardiometabolic disease risk","cognitive function","2026-05-18",{"date":204,"type":34},"2026-05-20",{"date":206,"type":34},"2025-09-30",{"date":208,"type":22},"2026-10",{"name":210,"class":72},"Loughborough University",{"id":212,"slug":213,"hasResults":12,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":49,"sex":18,"minAge":19,"maxAge":138,"enrollmentInfo":218,"targetDuration":4,"studyType":23,"phases":220,"briefSummary":221,"conditions":222,"keywords":223,"overallStatus":225,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":226,"startDateStruct":227,"completionDateStruct":228,"leadSponsor":230,"locationsCount":4},"100640656","phase-1-safety-and-drug-concentrations-of-regn20934-in-adults-with-overweight-or-obesity-100640656","NCT07594093","Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity","A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of REGN20934 in Adult Participants With Overweight or Obesity","Key Inclusion Criteria:\n\n1\\. Has a Body Mass Index (BMI) 25 to 35 kg\u002Fm\\^2\n\nKey Exclusion Criteria:\n\n1. A self-reported change of body weight \\>5 kg within approximately 90 days of visit 2\n2. History of type 1 or type 2 diabetes\n3. History of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric, or neurological disease, as defined in the protocol\n\nNote: Other protocol defined inclusion\u002Fexclusion criteria apply",{"count":219,"type":22},90,[142],"This study will test a study drug called REGN20934 to see how safe and well tolerated this drug is, as well as how the drug is processed in the body for participants with overweight or obesity.\n\nThe study is looking at:\n\n* What side effects REGN20934 might cause\n* How much REGN20934 is in the blood at different times\n* If the body makes antibodies to REGN20934",[29],[88,224],"Obesity or without diabetes","NOT_YET_RECRUITING",{"date":202,"type":34},{"date":63,"type":22},{"date":229,"type":22},"2027-02-22",{"name":231,"class":41},"Regeneron Pharmaceuticals",{"id":233,"slug":234,"hasResults":12,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":238,"eligibilityCriteria":239,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":23,"phases":242,"briefSummary":243,"conditions":244,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":255},"100380083","promote-weight-loss-in-obese-peripheral-artery-disease-pad-patients-to-prevent-mobility-loss-100380083","NCT04228978","Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss","PROmote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to preVEnt Mobility Loss: The PROVE Trial","PROVE","Inclusion criteria are a) presence of PAD; b) BMI\\> 25 kg\u002Fm2; c) Age \\>= 18. The diagnosis of PAD will be based on the following. First, an ankle brachial index (ABI) value \\\u003C= 0.90, which is a well-accepted standard for diagnosing PAD. People with a toe brachial index of \\\u003C=0.70, performed at the study visit, will be eligible. Second, people with an ABI of \\>0.90 and \\\u003C=1.00 who experience a 20% or greater drop in ABI in either leg after the heel-rise test will also be included. Third, potential participants with an ABI \\> 0.90 who provide vascular laboratory evidence or angiographic evidence of PAD will be included. Prior vascular laboratory evidence consists of objective evidence of PAD including toe brachial index (TBI) \\\u003C 0.70, Duplex measure showing 70% stenosis or greater, a post-exercise ABI drop in either leg of 20% or greater, or ABI values \\\u003C= 0.90. Angiographic evidence of PAD consists of a stenosis of 70% or greater in a lower extremity artery. Fourth, people with a history of lower extremity revascularization who do not meet the criterion above and have an ABI \\> 0.90 with a 20% or higher drop in ABI after an exercise test will be eligible if they have symptomatic PAD. Symptomatic PAD will be defined as leg symptoms associated with exertion that resolved within 10 minutes of rest. The presence of symptomatic PAD will be determined based on the claudication questionnaire, the six-minute walk, or principal investigator interview\u002Fdiscussion with the potential participant. The post-exercise ABI drop will be measured by obtaining an ABI, having the participant exercise, and then immediately repeating the ABI. The exercise may consist of either the six-minute walk test or the heel-rise test. The heel-rise test consists of 50 heel rises at a rate of one per second. From the beginning of the trial until early 2023, we used the BMI inclusion criterion of \\> 28 kg\u002Fm2 because overweight and obesity are defined as a BMI of 25 to 29 kg\u002Fm2 and \\> 30 kg\u002Fm2, respectively, and because in our PAD cohorts, those with BMI \\> 28 kg\u002Fm2 have significantly greater functional impairment and faster functional decline than those with BMI of 20-28 kg\u002Fm2. In order to increase the rate of recruitment, on 1\u002F19\u002F2022, investigators reduced the BMI inclusion criterion to \\> 25 kg\u002F m2. People with BMI above 25 are overweight or obese and therefore are expected to benefit from the healthy lifestyle intervention.\n\nExclusion Criteria:\n\n1. Above or below knee amputation, critical limb ischemia, or wheelchair confinement.\n2. Walking is limited by a condition other than PAD.\n3. Failure to complete the study run-in, defined as not entering at least 800 Kcal of consumed calories per day for at least five days during the 14-day run-in\\*.\n4. Major surgery, coronary or leg revascularization in the past 3 months or anticipated in the next year.\n5. Experienced a heart attack or stroke in the past 3 months.\n6. Major medical illness including lung disease requiring oxygen or life-threatening illness, Parkinson's disease, a life-threatening illness with life expectancy less than six months, or cancer requiring treatment in the previous two years. \\[NOTE: potential participants may still qualify if they have had treatment for an early stage cancer in the past two years and the prognosis is excellent.\n7. Mini-Mental Status Examination (MMSE) score \\\u003C 23, dementia and substance abuse. Potential participants with an MMSE score of less than 23 may be eligible if the principal investigator determines that their lower score is due to reasons other than poor cognition. Other potential reasons for lower scores include poor literacy or that English is not their first language.\n8. History of being treated for new onset or an acute episode of schizophrenia or psychosis in the past 6 months.\n9. Hospitalization for a psychiatric disorder in the past 6 months.\n10. BMI \\> 45 kg\u002Fm2\n11. History of a significant eating disorder that has been active within the past 5 years or any weight loss treatment in the past 6 months. Weight loss treatment includes weight watchers, any history of weight loss surgery, and using weight loss medications now or in the past six months.\n12. Weight gain or loss of more than 25 pounds in the past six months\n13. Potential participants unwilling\u002Funable to use a smart phone and unwilling to attend weekly study sessions.\n14. Excessive alcohol use, defined as \\>14 drinks\u002Fweek in men and \\> 10 alcoholic drinks\u002Fweek in women.\n15. Current ulcer on bottom of foot\n16. Current participation in supervised treadmill exercise, participation in supervised treadmill exercise in the past three months, or planning to participate in supervised treadmill exercise in the next year\n17. Increase in angina or angina at rest. Potential participants may become eligible following an abnormal baseline treadmill stress test if they have evidence of an absence of coronary ischemia based on testing with their own physician.\n18. Non-English speaking\n19. Visual impairment that limits walking ability\n20. Currently walking regularly for exercise at a level comparable to the amount of exercise prescribed in the intervention\n21. Participation in or completion of a clinical trial in the previous three months. \\[NOTE: after completing a stem cell or gene therapy intervention, participants will become eligible after the final study follow-up visit of the stem cell or gene therapy study so long as at least six months have passed since the final intervention administration. After completing a supplement or drug therapy (other than stem cell or gene therapy), participants will be eligible after the final study follow-up visit as long as at least three months have passed since the final intervention of the trial.\\]\n22. In addition to the above criteria, investigator discretion will be used to determine if the trial is unsafe or not a good fit for the potential participant",{"count":241,"type":22},212,[54],"The PROVE Trial is a randomized clinical trial that will determine whether a weight loss intervention combined with walking exercise achieves greater improvement or less decline in six-minute walk distance at 12 month follow-up than walking exercise alone in people with PAD and BMI\\>25 kg\u002Fm2. The intervention uses a Group Mediated Cognitive Behavioral framework, connective mobile technology, remote monitoring by a coach, and a calorie restricted Dietary Approaches to Stop Hypertension (DASH)-derived Optimal Macronutrient Intake Trial for Heart Health (OMNIHeart) diet.\n\n212 participants with PAD and BMI \\> 25 kg\u002Fm2 will be randomized to one of two groups: weight loss + exercise (WL+EX) vs. exercise alone (EX). Participants will be randomized at Northwestern, Tulane University, and University of Minnesota. Our primary outcome is change in six-minute walk distance at 12-month follow-up. Secondary outcomes are change in 6-minute walk distance at 6-month follow-up and change in exercise adherence, physical activity, patient-reported walking ability (measured by the Walking Impairment Questionnaire (WIQ) distance score), and mobility (measured by the Patient-Reported Outcomes Measurement Information System \\[PROMIS\\] mobility questionnaire) at 12-month follow-up. Tertiary outcomes are perceived exertional effort (measured by the Borg scale at the end of the 6-minute walk at 12-month follow-up), and diet quality. Exploratory outcomes consist of change in the short physical performance battery (SPPB), the WIQ stair climbing and walking speed scores, and calf muscle biopsy measures at 12-month follow-up. Study investigators will perform calf muscle biopsies in 50 participants to compare changes in mitochondrial biogenesis and activity, capillary density, and inflammation between WL+EX vs. EX.",[245,29],"Peripheral Artery Disease","2026-05-05",{"date":248,"type":34},"2026-05-07",{"date":250,"type":34},"2020-03-01",{"date":252,"type":22},"2027-08-01",{"name":254,"class":72},"Northwestern University",7,{"id":257,"slug":258,"hasResults":12,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":262,"eligibilityCriteria":263,"healthyVolunteers":49,"sex":18,"minAge":19,"maxAge":138,"enrollmentInfo":264,"targetDuration":4,"studyType":23,"phases":266,"briefSummary":267,"conditions":268,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":278},"100604629","phase-1-a-study-of-ly4064912-in-healthy-participants-and-with-overweight-or-obesity-100604629","NCT07152002","A Study of LY4064912 in Healthy Participants and With Overweight or Obesity","A Phase 1, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4064912 in Healthy Participants and Participants With Overweight or Obesity","YHAA","Inclusion Criteria:\n\n* Age is 21-65 years old at Singapore Sites\n* Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring\n\nPart A: Body Mass Index (BMI) within the range greater than or equal to 21 and less than 30 kilogram per square meter (kg\u002Fm²)\n\nPart B: a BMI greater than or equal to 27 and less than 45 kg\u002Fm²\n\nPart C: a BMI greater than or equal to 21 and less than 35 kg\u002Fm²\n\n* Parts A and C: Participants must weigh 60 kilograms (kg) or more at screening\n* Have had a less than 5% change in body weight for 3 months before screening\n* Safety laboratory tests are within normal reference range\n\nExclusion Criteria:\n\n* Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the investigational product; or of interfering with the interpretation of data\n* Have history of diabetes (except gestational diabetes) or current diagnosis of diabetes (any form), or have HbA1c greater than or equal to 6.5% (48 millimole per mole (mmol\u002Fmol)) at screening\n* Are individuals of childbearing potential (IOCBP).",{"count":265,"type":22},144,[142],"The purpose of this study is to evaluate how well LY4064912 is tolerated and what side effects may occur in healthy participants and participants with overweight and obesity - global. The study drug will be administered either subcutaneously (SC) (under the skin) or infusion intravenously (IV) (into a vein in the arm).\n\nBlood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.",[29,269],"Healthy","2026-04-17",{"date":272,"type":34},"2026-04-20",{"date":274,"type":34},"2025-08-28",{"date":276,"type":22},"2026-11",{"name":40,"class":41},3,{"id":280,"slug":281,"hasResults":12,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":4,"eligibilityCriteria":285,"healthyVolunteers":49,"sex":18,"minAge":19,"maxAge":138,"enrollmentInfo":286,"targetDuration":4,"studyType":23,"phases":288,"briefSummary":289,"conditions":290,"keywords":4,"overallStatus":225,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":4},"100633897","phase-1-a-single-ascending-dose-study-of-syh2082-injection-in-healthy-participants-100633897","NCT07532655","A Single Ascending Dose Study of SYH2082 Injection in Healthy Participants","A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose of SYH2082 Injection in Healthy Participants","Inclusion Criteria:\n\n* Fully understands the content, procedures, and possible adverse reactions of the study, and voluntarily signs the ICF before the study;\n* At screening, age 18-65 years (inclusive, at the time of signing the ICF), male or female;\n* At screening, body weight ≥50 kg for males and ≥45 kg for females; body mass index (BMI) between 22.0 and 40.0 kg\u002Fm2 (inclusive);\n* Body weight change ≤5% within 3 months prior to screening (including the screening period);\n* From the time of signing the ICF until 6 months after the last dose, the participant (including their partner) has no plans for childbirth and agrees to use highly effective contraceptive measures.\n\nExclusion Criteria:\n\n* Known or suspected allergy to glucagon-like peptide-1 (GLP-1) or Glucose dependent insulinotropic polypeptide (GIP) receptor agonists or any component of the investigational product; or has an allergic constitution (allergic to multiple drugs and foods);\n* Abnormal results in vital signs, physical examination, laboratory tests, and ECG that are judged by the investigator to be clinically significant within the screening period. Specifically, the following conditions are not excluded:\n\n  1. Systolic blood pressure (SBP) \\\u003C 160 mmHg, diastolic blood pressure (DBP) \\\u003C 100 mmHg;\n  2. Fasting TG ≤ 5.6 mmol\u002FL, fasting TC ≤ 7.5 mmol\u002FL, fasting LDL-C ≤ 5 mmol\u002FL, and abnormal fasting HDL-C;\n  3. Alanine aminotransferase (ALT) \\\u003C 2 × ULN, aspartate aminotransferase (AST) \\\u003C 2 × ULN, gamma-glutamyl transferase (GGT) \\\u003C 2.5 × ULN, and total bilirubin (TBIL) \\\u003C 1.5 × ULN. Participants with values outside the normal range may be included if the abnormality is deemed benign by the investigator (e.g., Gilbert's syndrome);\n* History or laboratory evidence of diabetes mellitus (type 2, type 1, or other forms of diabetes), including fasting glucose of ≥126 mg\u002FdL (7.0 mmol\u002FL) and\u002For HbA1c ≥ 6.5% within the screening period;\n* With any previous episode of hypoglycemia or with screening fasting glucose \\\u003C 3.9mmol\u002FL (even on a single sample);\n* With obesity due to identifiable endocrinologic, genetic or syndromic causes;\n* Meets any of the following criteria within the screening period:\n\n  1. Calcitonin ≥25 ng\u002FL;\n  2. Estimated glomerular filtration rate (eGFR) \\\u003C80 mL\u002Fmin\u002F1.73m2\n  3. Thyroid-stimulating hormone (TSH) outside the normal reference range;\n  4. Fasting serum amylase and\u002For lipase \\>1.5× ULN.\n* At screening, has a prolonged QT\u002FQTc interval (QTcF \\>450 ms for males and QTcF\\>470 ms for females), or a history of risk factors for Torsades de Pointes (e.g., cardiac failure\u002Fcardiomyopathy or a family history of long QT syndrome), or is currently taking concomitant medications that prolong the QT\u002FQTc interval;\n* Positive for any of the following: Hepatitis B surface antigen, Hepatitis C virus antibody, human immunodeficiency virus antibody, or syphilis serology;\n* Significant history or clinical manifestation of any metabolic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, immune or psychiatric disorder as determined by the Investigator or medical designees;\n* History of severe trauma or major surgery within 3 months prior to screening, or plans to undergo surgery or any procedures requiring general anesthesia or sedation during the study period;\n* History of thyroid nodules diagnosed as C-TIRADS category 3 or higher;\n* Personal or family history of medullary thyroid cancer (MTC) or multiple endocrine neoplasia syndrome type 2, or a personal history of pancreatitis or gallbladder\u002Fgallstone disease;\n* History of malignancy, except for non-melanoma skin cancer excised more than 1 year prior to Screening and cervical intraepithelial neoplasia that has been successfully cured more than 2 years prior to Screening;\n* History of major depressive disorder, including any medication or psychological therapy, in the last 2 years, or any clinically significant mental health condition;\n* Lifetime history of any suicide attempts or suicide behavior according to the C-SSRS, or any suicidal ideation in the last two years according to the C-SSRS;\n* Non-suicidal self-injury more than 5 years ago is permissible, if it is clear there was no suicidal intent. Participants should be excluded if any doubt;\n* History of gastric emptying abnormalities (e.g., gastric outlet obstruction) or severe chronic gastrointestinal diseases (e.g., inflammatory bowel disease, active ulcer);\n* History of gastrointestinal surgery that could lead to malabsorption, or long-term use of drugs that directly affect gastrointestinal motility. For example: has undergone bariatric surgery or procedures (e.g., gastric banding) within 3 months prior to screening;\n* History of use GLP-1 or GIP receptor agonists or any drug or product that may cause weight changes and affect weight assessment considered by the investigator within 3 months prior to screening;\n* Has dermatitis or other skin abnormalities (including tattoos) at or around the injection site;\n* Use of any prescription drugs, within 2 weeks prior to dosing or no more than 5 half-life (whichever is longer) after the last use of the above drugs. Non-prescription drugs, herbal preparations and supplements excluded 7 days prior to dosing, and allow short term use of paracetamol and anti-inflammatory drug use within the 7 days prior to dosing, within investigator discretion;\n* Use of drugs that may affect glucose metabolism (e.g., systemic steroids, non-selective β-blockers, monoamine oxidase inhibitors) within 1 month prior to screening, or no more than 5 half-life (whichever is longer) after the last use of the above drugs;\n* Average weekly alcohol consumption exceeding 21 units (males) \u002F 14 units (females) within 3 months prior to screening (1 unit ≈ 375 mL of mid-strength beer (3.5% alcohol\u002Fvolume), 100 mL of wine (13.5% alcohol\u002Fvolume), or 30 mL of spirits (40% alcohol\u002Fvolume)), or has a positive alcohol breath test, or is unable to abstain from alcohol during the hospital stay;\n* Smokes more than 10 cigarettes per day on average within 3 months prior to screening, or is unable to stop using any nicotine products during the hospital stay;\n* Consumes excessive amounts of tea, coffee, and\u002For caffeinated beverages (average of more than 8 cups per day, 1 cup ≈ 250 mL) within 3 months prior to screening, or is unable to stop consumption during the hospital stay;\n* Engaged in strenuous exercise within 48 hours prior to clinic visits, such as weightlifting, sprinting, long-distance running, cycling, swimming, or playing football;\n* History of drug abuse within 6 months prior to screening, or a positive drug abuse screening test at screening and D-2;\n* Has donated blood or plasma within 30 days prior to screening or had a loss of whole blood of more than 500ml within the 30 days prior to screening, or receipt of a blood transfusion within one year prior to screening;\n* History of needle or blood phobia, difficulty with blood collection, or unable to tolerate intravenous blood draws;\n* Has special dietary requirements and cannot adhere to the standardized diet and schedule;\n* Female participants who are pregnant, lactating, or have a positive pregnancy test result at screening and D-2;\n* Has received an investigational agent\u002Fdevice in another clinical study within 3 months or 5 half-lives prior to Screening (whichever is longer), or is currently participating in or plans to participate in another drug or medical device clinical study during the study period;\n* Participants whom the investigator considers to have other factors making them unsuitable for participation in this trial.",{"count":287,"type":22},44,[142],"To evaluate the safety and tolerability of single dose of SYH2082 Injection in healthy participants.",[29],"2026-04-09",{"date":293,"type":34},"2026-04-16",{"date":295,"type":22},"2026-04-14",{"date":297,"type":22},"2027-02-09",{"name":299,"class":41},"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",{"id":301,"slug":302,"hasResults":12,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":4,"eligibilityCriteria":306,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":307,"enrollmentInfo":308,"targetDuration":4,"studyType":23,"phases":310,"briefSummary":311,"conditions":312,"keywords":313,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":73},"100579903","phase-1-the-safety-tolerability-and-pharmacokinetics-of-of-syh9017-in-chinese-participants-with-overweight-and-obesity-100579903","NCT06830343","The Safety, Tolerability, and Pharmacokinetics of of SYH9017 in Chinese Participants With Overweight and Obesity","A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic of SYH9017 in Chinese Participants With Overweight and Obesity Following Single and Multiple Doses","Inclusion Criteria:\n\n1. Chinese male or female adult participants aged 18-60 years (inclusive) with overweight or obesity, with no less than one-third of the participants of either gender;\n2. SAD phase: Body Mass Index (BMI) = weight (kg)\u002Fheight\\^2 , with BMI in the range of 24.0-28.0 kg\u002Fm\\^2 (inclusive); MAD phase: Weight ≥70 kg (for males) or ≥60 kg (for females), and BMI = weight (kg)\u002Fheight\\^2 , with BMI ≥28.0 kg\u002Fm\\^2;\n3. Weight change \\\u003C5% in the 3 months prior to screening (can be based on self-report); calculated as: (weight 12 weeks before screening - weight at screening) \u002F weight at screening \\* 100%;\n4. Vital signs, physical examination, 12-lead electrocardiogram, chest X-ray (anteroposterior view), abdominal color Doppler ultrasound, clinical laboratory tests (complete blood count, urinalysis, blood biochemistry, glycated hemoglobin, coagulation function, infectious disease screening, thyroid function, calcitonin, etc.) show normal results or abnormal results deemed not clinically significant by the investigator;\n5. Able to read and understand the written informed consent related to the study information, fully aware of the study content, process, and possible adverse reactions, voluntarily sign the informed consent form before the trial, and ensure that they will personally participate in any procedures; Participants and their partners agree to use effective non-hormonal contraception methods (such as condoms, inert intrauterine devices, female barrier methods \\[cervical cap or diaphragm with spermicide\\], vaginal contraceptive rings, etc.) from the time of signing the informed consent form until 6 months after the last dose, or have already adopted permanent contraception measures (such as bilateral tubal ligation, vasectomy, etc.); Male participants do not plan to donate sperm from the time of signing the informed consent form until 6 months after the last dose, and female participants do not plan to donate eggs from the time of signing the informed consent form until 6 months after the last dose.\n\nExclusion Criteria:\n\n1. A history of severe drug or food allergies, or any participant who is judged by the investigator to potentially be allergic to the investigational drug;\n2. A history of significant diseases involving the pancreas, liver, kidneys, gastrointestinal tract, skin, cardiovascular system, respiratory system, hematological system, central nervous system, or other conditions that may endanger the safety of participants or affect the absorption, metabolism, or excretion of the study drug, and are deemed unsuitable for inclusion by the investigator;\n3. A history of malignancy (except for cured basal cell carcinoma of the skin or carcinoma in situ of the cervix), psychiatric disorders (such as depression, schizophrenia, bipolar disorder, or a history of suicidal ideation or behavior), epilepsy, acute biliary disease, or confirmed acute or chronic pancreatitis; participants judged by the investigator to be unsuitable for participation in this clinical study;\n4. Diagnosed with diabetes, thyroid dysfunction (abnormal TSH, FT3, or FT4 levels), Cushing's syndrome, polycystic ovary syndrome, a history of glucagonoma or pheochromocytoma, or other endocrine diseases that may affect glucose metabolism, or has experienced ≥2 episodes of severe hypoglycemia or recurrent symptomatic hypoglycemia;\n5. A personal or family history of medullary thyroid carcinoma (MTC) or a history of multiple endocrine neoplasia type 2 (MEN2).\n6. Any one of the following criteria is met:\n\n   i. Participants with one or more abnormal vital signs: body temperature \\\u003C35.5°C or \\>37.2°C, pulse rate \\\u003C50 beats per minute or \\>100 beats per minute, systolic blood pressure ≥160 mmHg or \\\u003C90 mmHg, diastolic blood pressure ≥100 mmHg or \\\u003C60 mmHg. A single retest is allowed, and participants with abnormalities in both tests will be excluded; ii. Any of the following laboratory abnormalities: a) Fasting plasma glucose ≥7.0 mmol\u002FL or fasting plasma glucose \\\u003C3.9 mmol\u002FL or HbA1c level \\>6.5%; b) AST or ALT \\>2 times the upper limit of normal (ULN), total bilirubin \\>1.5 times ULN, deemed clinically significant by the investigator; c) Estimated glomerular filtration rate (eGFR) \\\u003C90 mL\u002Fmin\u002F1.73m²; d) Serum amylase or lipase \\>3 times ULN; e) Blood low-density lipoprotein cholesterol (LDL-C) ≥4.40 mmol\u002FL; f) Triglycerides (TG) ≥5.65 mmol\u002FL.\n7. During the multiple-dose phase: Use of any approved or unapproved drugs or products that may affect body weight within 6 months prior to screening, including but not limited to orlistat, phentermine-topiramate, naltrexone-bupropion, systemic steroid medications (administered intravenously, orally, or intra-articularly), antidepressants (selective serotonin reuptake inhibitors (SSRIs), noradrenaline reuptake inhibitors (SNRIs), tricyclics, tetracyclics, etc.), psychotropic medications or sedative drugs (such as imipramine, amitriptyline, mirtazapine, paroxetine, phenelzine, chlorpromazine, thioridazine, clozapine, olanzapine, valproate, valproate derivatives, lithium salts), etc.; or use of traditional Chinese medicines, health supplements, meal replacements, or antibiotic drugs or probiotic preparations that influence gut microbiota and thereby affect body weight; or having undergone bariatric surgery within 6 months prior to screening;\n8. Use of glucagon-like peptide-1 (GLP-1) receptor agonists, GLP-1 analogs (such as liraglutide, dulaglutide, lixisenatide, exenatide, albiglutide, benraliptide, polyethylene glycol loxenatide, etc.) or any dipeptidyl peptidase-4 (DPP-4) inhibitors or glucose-dependent insulinotropic polypeptide (GIP) receptor agonists within 6 months prior to signing the informed consent form.\n9. Use of any prescription medications, over-the-counter medications, traditional Chinese patent medicines, herbal remedies, vitamin dietary supplements, or health products within 4 weeks prior to signing the informed consent form;\n10. Habitual intake of or consumption of excessive amounts of xanthine or caffeine-containing foods, beverages, or other substances that may affect drug absorption, distribution, metabolism, or excretion within 1 month prior to screening or within 72 hours before using the investigational drug. Examples include: coffee (more than 1100 mL per day), tea (more than 2200 mL per day), cola (more than 2200 mL per day), energy drinks (more than 1100 mL per day), chocolate (more than 510 g per day);\n11. Undergone surgery (including cosmetic, dental, and oral surgeries) within 6 months prior to screening or planned during the trial period, or plans to engage in vigorous physical activity (including contact sports or collision sports) during the trial period;\n12. A history of drug abuse or a positive drug screening test within 1 year prior to signing the informed consent form;\n13. Loss of blood or donation of more than 400 mL of blood within 3 months prior to signing the informed consent form, or receipt of blood transfusions or use of blood products;\n14. Consumption of more than 14 units of alcohol per week (1 unit = 285 mL of beer; 25 mL of spirits; 150 mL of wine) within 3 months prior to signing the informed consent form, or consumption of any alcohol-containing products within 48 hours before using the investigational drug; positive baseline alcohol test (\\>0 mg\u002F100 mL) or inability to abstain from alcohol during the trial period;\n15. Smoking ≥5 cigarettes daily within 6 months prior to signing the informed consent form, smoking within 48 hours before using the investigational drug, or inability to cease the use of any tobacco products during the trial period;\n16. Participation in any clinical trial involving investigational drugs or medical devices within 3 months prior to signing the informed consent form;\n17. Pregnant and\u002For breastfeeding women, or women of childbearing potential with a positive pregnancy test at screening and before dosing;\n18. A history of vasovagal syncope or hemophobia, or difficulty with venipuncture for any reason, making it intolerable;\n19. Difficulty with subcutaneous injection administration;\n20. Any other factors deemed by the investigator to make the participant unsuitable for participation in the trial.","60 Years",{"count":309,"type":22},66,[142],"This is a randomized, double-blind, single-center, dose-escalation, single ascending dose and multiple ascending dose study of SYH9017 in Chinese participants with overweight and obesity.",[29],[314],"overweight or obesity","2026-04-03",{"date":317,"type":34},"2026-04-06",{"date":319,"type":34},"2025-02-27",{"date":321,"type":22},"2026-10-01",{"name":323,"class":41},"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.",{"id":325,"slug":326,"hasResults":12,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":330,"eligibilityCriteria":331,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":184,"enrollmentInfo":332,"targetDuration":4,"studyType":23,"phases":334,"briefSummary":335,"conditions":336,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":154},"100615425","phase-3-extension-study-of-the-phase-3-clinical-study-of-gzr18-injection-for-weight-loss-100615425","NCT07292441","Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss","A Multicenter Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss","GZR18-BWM-303","Inclusion Criteria:\n\n1. Subjects who participated in the original study, completed the last dose at W50, EOT visit at W52 and safety follow-up visit at W55 of either original study, with last dose at W50 ≥ 24 mg (including blinded dose of placebo).\n2. Subjects with BMI \\> 18.5 kg\u002Fm² at W55 of the original study and before randomization at Visit 2 (V2) of this study, who are assessed by the investigator as suitable for participating in this study.\n3. Subjects of childbearing potential with no birth plan from the signing of ICF to 8 weeks after the last dose, willingness to take effective contraceptive measures, and no plan for sperm or ovum donation. Non-lactating women of childbearing potential (WOCBP) with a negative pregnancy test result before randomization at V2 in this study.\n4. Able to understand the procedures and methods of this study, willing and able to maintain a regular diet and exercise lifestyle during the study period, willing and able to undergo subcutaneous injections of the investigational medicinal product (IMP), and willing to sign the ICF voluntarily.\n\n   \\-\n\nExclusion Criteria:\n\n1. Subjects who used Semaglutide (Wegovy®) in the original study.\n2. Subjects with a previous diagnosis of any type of diabetes mellitus (excluding gestational diabetes mellitus).\n3. Subjects with FPG ≥ 7.0 mmol\u002FL or HbA1c ≥ 6.5% in the central laboratory test at W52 visit of the original study.\n4. Subjects who plan to participate in another clinical study of an investigational medicinal product or device, or receive drug or non-drug therapies that affect body weight (excluding diet and exercise control) before completing all scheduled assessments in this clinical study.\n5. Subjects with any other factors (including but not limited to previous compliance in the original study) that may affect the efficacy or safety evaluation of this study as judged by the investigator.\n\n   \\-",{"count":333,"type":22},500,[25],"This is a Phase 3 extension study conducted in subjects who have received GZR18 Injection once every 2 weeks (Q2W) for weight loss treatment for 52 weeks, aiming to explore the effect and safety of continuous injection of GZR18 Injection once every 4 weeks (Q4W) for 24 weeks on body weight.\n\nIn this study, it is planned to include subjects who have participated in the original study and completed the study contents of the original protocol. All subjects will maintain a regular diet and exercise lifestyle during the study.",[29],"2026-03-10",{"date":339,"type":34},"2026-03-11",{"date":341,"type":34},"2026-01-22",{"date":343,"type":22},"2027-10",{"name":345,"class":41},"Gan & Lee Pharmaceuticals.",{"id":347,"slug":348,"hasResults":12,"nctId":349,"briefTitle":350,"officialTitle":350,"acronym":4,"eligibilityCriteria":351,"healthyVolunteers":49,"sex":182,"minAge":19,"maxAge":352,"enrollmentInfo":353,"targetDuration":4,"studyType":23,"phases":355,"briefSummary":356,"conditions":357,"keywords":358,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":73},"100491105","ndpp-nextgen-a-clinical-trial-to-reduce-intergenerational-obesity-and-diabetes-risks-100491105","NCT05674799","NDPP-NextGen: A Clinical Trial to Reduce Intergenerational Obesity and Diabetes Risks","Inclusion Criteria:\n\n* Established patient at Denver Health or Atrium Health Wake Forest Baptist\n* Biologically female (inclusive of all gender identities)\n* Aged 18-39 years\n* English- or Spanish-speaking\n* BMI ≥25 kg\u002Fm2 (≥23 kg\u002Fm2 if Asian race)\n* Activities that lead to pregnancy in past 3 months\n* Interested in pregnancy within 24 months, including:\n\n  1. High interest (actively trying to conceive)\n  2. General interest (not actively trying but wanting to become pregnant in the foreseeable future)\n  3. Neutral interest (not planning pregnancy or using contraception for religious reasons)\n\nExclusion Criteria:\n\n* Currently pregnant\n* Non-gestational diabetes (type 1, type 2)\n* Long-acting contraceptives (intrauterine device, implant, injection) with plans to continue for \\>1 year (barrier \\& short-acting hormonal contraception permitted given ease of discontinuing to facilitate pregnancy)\n* Medical procedures (e.g., tubal ligation, hysterectomy) or conditions that impede pregnancy\n* Documented infertility or unsuccessfully trying to conceive for ≥12 months\n* Prior participation in the NDPP\n* History of bariatric surgery\n* Use of GLP-1s in last year\n* Currently receiving clinical obesity treatment","39 Years",{"count":354,"type":22},403,[54],"The goal of this clinical trial is to test an enhanced version of the National Diabetes Prevention Program (NDPP-NextGen) that is tailored to young women in childbearing years. The investigators will recruit 360 women aged 18-39 years with overweight\u002Fobesity who are not currently pregnant, but likely to conceive within 24 months. Women will be randomized to NDPP-NextGen or a usual care control group. The NDPP-NextGen group will participate in the adapted NDPP online group class across 12 months, and the control group will get a packet of information about how to be healthy before, during and after pregnancy.\n\nThe main goals of the study are:\n\n1. to assess effects of NDPP-NextGen on pre-pregnancy blood sugar and early pregnancy BMI\n2. to assess effects of NDPP-NextGen on weight gain and behavioral outcomes during pregnancy\n3. to explore effects of NDPP-NextGen on infant's percentage of fat tissue at birth\n\nAll participants will complete up to 4 research visits: baseline, conception, mid-pregnancy, and delivery. These visits will include:\n\n1. Questionnaires about health, diet, activity, smoking, self-confidence, and depression\n2. Body size measurements\n3. Fasted blood draws\n\nParticipants will also be asked to weigh themselves weekly using home scales that are connected to the research database. At the delivery visit, investigators will measure the baby's body size and collect a cord blood sample.",[29],[359,360,361,60,362,363,364,88,365,366,367,368,369,370,371,372,373,374,375,376],"Body mass index","Pre-conception","Diabetes Mellitus","Gestational diabetes","Neonatal adiposity","Maternal and Child Health","Obese","Pregnancy","Randomized Control Trial","Weight","adverse maternal outcomes","Diabetes Prevention Program","glucose","gestational weight gain","lifestyle intervention","usual care","remote delivery","young women","2026-02-25",{"date":379,"type":34},"2026-02-27",{"date":381,"type":34},"2023-04-08",{"date":383,"type":22},"2028-05-31",{"name":385,"class":72},"Wake Forest University Health Sciences",{"id":387,"slug":388,"hasResults":12,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":4,"eligibilityCriteria":392,"healthyVolunteers":12,"sex":18,"minAge":307,"maxAge":184,"enrollmentInfo":393,"targetDuration":4,"studyType":23,"phases":395,"briefSummary":396,"conditions":397,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":401,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":73},"100623386","phase-1-the-efficacy-and-safety-of-metformin-intervention-in-elderly-overweight-or-obesity-with-mild-cognitive-impairment-100623386","NCT07395960","The Efficacy and Safety of Metformin Intervention in Elderly Overweight or Obesity With Mild Cognitive Impairment","The Efficacy and Safety of Metformin Intervention in Elderly Overweight or Obesity With Mild Cognitive Impairment by a Single-center, Randomized, Placebo-controlled Interventional Study (Include Elderly Patients With Obesity or Overweight)","Inclusion Criteria:\n\n* Age: 60 - 75 years old\n* Body Mass Index: ≥ 24 kg\u002Fm2\n* Glycated Hemoglobin \\\u003C 8.5%\n* Moca Scale score: 20-26 points (education\\> 10 years) or 20-25 points (education≤ 10 years)\n* Sign the informed consent form\n\nExclusion Criteria:\n\n* Any hypoglycemic drugs have been used within 8 weeks prior to enrollment\n* Type 1 diabetes\n* Unable to undergo central nervous system magnetic resonance examination\n* History of alcohol or drug addiction\n* Severe gastrointestinal diseases, history of gastrointestinal surgery, severe cardiac or pulmonary dysfunction, malignant tumors and other diseases\n* Abnormal liver function (liver enzyme indicators more than 2.5 times the upper limit of the reference range) or abnormal kidney function (estimated glomerular filtration rate\\\u003C 45 ml\u002Fmin)\n* There are diseases such as cerebral infarction and vascular dementia\n* There are conditions judged by the investigator as being unsuitable for enrollment",{"count":394,"type":22},54,[142,85],"The prevalence of cognitive impairment in elderly obese patients is high, and the burden on families and society is heavy. Early intervention for mild cognitive impairment (MCI) is of great value. Central nervous system insulin resistance plays a role in the pathogenesis of cognitive impairment, and functional magnetic resonance imaging(fMRI) can evaluate cognitive impairment by observing central insulin resistance. Some large database studies of Type 2 Diabetes show that metformin is related to reducing the risk of dementia, but some studies have different conclusions, and there is few related study in elderly obese patients. The investigators speculate that metformin may improve cognitive dysfunction by improving central insulin resistance in elderly obese patients.\n\nA prospective, randomized controlled single center clinical cohort study will be conducted on 54 elderly obese patients with MCI. One group will receive metformin and lifestyle intervention, while the control group will receive simple lifestyle intervention. All subjects will be followed up for 26 weeks. Medical history collection, physical examination, and laboratory tests will be conducted before and after intervention, and the Montreal Cognitive Assessment Scale will be used for evaluation. Nasal insulin inhalation combined with fMRI will be used to evaluate central insulin resistance status as an objective basis for cognitive function evaluation. The main purpose of the study is to provide more accurate clinical research evidence for the prevention and treatment of MCI in elderly obese patients, in order to reduce the risk of developing dementia and alleviate the burden on families and society.",[398,29,399],"Mild Cognitive Impairment","Elderly","2026-01-31",{"date":36,"type":34},{"date":403,"type":34},"2025-09-01",{"date":405,"type":22},"2026-09-30",{"name":407,"class":72},"Fudan University",{"id":409,"slug":410,"hasResults":12,"nctId":411,"briefTitle":412,"officialTitle":412,"acronym":4,"eligibilityCriteria":413,"healthyVolunteers":49,"sex":18,"minAge":414,"maxAge":4,"enrollmentInfo":415,"targetDuration":4,"studyType":23,"phases":417,"briefSummary":418,"conditions":419,"keywords":421,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":425,"startDateStruct":427,"completionDateStruct":429,"leadSponsor":431,"locationsCount":73},"100498462","phase-2-taxi-roadmap-realizing-optimization-around-diet-and-physical-activity-100498462","NCT05770570","Taxi ROADmAP (Realizing Optimization Around Diet And Physical Activity)","Inclusion Criteria:\n\nFor COMIDA participants only:\n\n* Self-Identifies as Mexican American or Mexican\n* Seeking services at the VDS of the Mexican Consulate\n* Prefers to speak in Spanish\n* All adults at least 18 years of age\n* Screens as obese (an adult who has a Body Mass Index (BMI) 30 or higher) or overweight (an adult who has a BMI between 25 - 29.9)\n* Agrees to be audio recorded\n\nFor SANOS focus group participants only:\n\n* Self-identifies as Hispanic\u002FLatino;\n* Seeking services at VDS or VDS Mobile;\n* Prefers to speak in Spanish;\n* At least 18 years of age;\n* Screens as obese (BMI ≥ 30 kg\u002Fm\\^2) or overweight (BMI of 25 - 29.9 kg\u002Fm\\^2);\n* Agrees to be audio recorded\n\nFor SANOS RCT participants only:\n\n* Self-identifies as Hispanic\u002FLatino;\n* Seeking services at VDS or VDS Mobile;\n* Prefers to speak in Spanish;\n* At least 18 years of age;\n* Screens as obese (BMI ≥ 30 kg\u002Fm\\^2) or overweight (BMI of 25 - 29.9 kg\u002Fm\\^2);\n* Owns a cell phone capable of receiving text messages;\n* Agrees to be audio recorded\n\nFor Family COMIDA participants only:\n\n* Self-Identifies as Hispanic\u002FLatino\n* Seeking services at the VDS (or has used VDS services in the past) of the Mexican - Consulate or VDS Mobile\n* Prefers to speak in Spanish\n* At least 18 years of age\n* Has at least one child under age 18 living in the same household\n* Owns a cell phone capable of receiving text messages\n* Willing to receive text messages (3 texts per week for 3 months)\n* Owns an internet connected device (eg, cell phone, tablet, etc) capable of conducting teleconference calls (eg, Zoom)\n\nFor ROADmAP RCT participants only:\n\n* At least 21 years of age\n* Full-time (drives at least 35 hours per week) licensed taxi\u002FFHV driver\n* Driver for at least 6 months\n* Seeking Health Fairs (or has used Health Fairs services in the past)\n* Speaks English, French, Bengali, or Spanish\n* Screens a as obese (BMI ≥ 30 kg\u002Fm2 \\[≥25 kg\u002Fm2 for South Asians\\]) or overweight (BMI of 25 - 29.9 kg\u002Fm2 s \\[23- 24.9 kg\u002Fm2 for South Asians\\])\n\n  * (BMI cut-offs are lower for South Asians, per WHO and American Diabetes Association recommendations)\n* Owns a cell phone capable of receiving text messages\n* Agrees to be audio-recorded\n\nFor ROADmAP Phase 2 participants only:\n\n* At least 21 years of age\n* Driver who participated in ROADmAP RCT or manager at a taxi garage, Uber, Lyft or driver serving\u002Funion\u002Forganization\n* Agrees to be audio-recorded\n\nExclusion Criteria:\n\nFor COMIDA participants only:\n\n* Will not be in the NYC area for the study duration (3-4 months) Is pregnant or might be pregnant\n* Lactating women\n* Presence of a chronic disease such as cancer, kidney disease, liver disease, etc. (Individuals with diabetes, lactose intolerance, and high blood pressure MAY still participate in the study)\n* Has dietary restrictions (i.e. liquid diet)\n* Does not have a phone that accepts text messages or unwilling to accept text messages\n* Presence of a serious psychiatric or cognitive impairment likely to preclude meaningful informed consent and adherence to the protocol per the consenting professional\"s judgment\n* Has another family member already enrolled in COMIDA (as determined by patient report)\n\nFor SANOS focus group participants only:\n\n* Is pregnant or might be pregnant; lactating women;\n* Self-reported presence of a chronic disease such as cancer, kidney disease, liver disease, etc. (individuals with HTN and DM may still participate);\n* Has dietary restrictions (i.e. liquid diet);\n* Has a household member who has already participated (or agreed to participate);\n\nFor SANOS RCT participants only:\n\n* Is pregnant or might be pregnant; lactating women; for the study duration (6 months)\n* Self-reported presence of a chronic disease such as cancer, kidney disease, liver disease, etc. (individuals with HTN and DM may still participate); restricting diet;\n* Currently has dietary restrictions (i.e. liquid diet);\n* Has a household member who has already participated (or agreed to participate);\n* Has already participated in the study\n* Will not be in the NY Metropolitan area for the study duration (6 months) Works for or with the Mexican consulate (including employment and\u002For collaborative or volunteer services)\n\nFor Family COMIDA participants only:\n\n* Is pregnant or might be pregnant; lactating women for the study duration (3 months)\n* Will not be in the NY Metropolitan area for the study duration (3 months) Presence of a chronic disease such as cancer, kidney disease, liver disease, etc. (Individuals with diabetes, lactose intolerance, and high blood pressure MAY still participate in the study)\n* Has dietary restrictions (i.e. liquid diet)\n* Has another family member who has already participated in COMIDA or SANOS\n* Has already participated in the study\n* Works for or with the Mexican consulate (including employment and\u002For collaborative or volunteer services)\n\nFor ROADmAP RCT participants only:\n\n* Is pregnant or might be pregnant; lactating women; for the study duration (12 months)\n* Self-reported presence of a chronic disease such as cancer, kidney disease, liver disease, etc. (individuals with HTN and DM may still participate) that may restrict diet\n* Currently has dietary restrictions (i.e. liquid diet)\n* Has a household member who has already participated (or agreed to participate)\n* Has already participated in the study\n* Will not be in the NY Metropolitan area for 6 months from study enrollment\n* Is currently taking Ozempic, Wegovy, Mounjaro, Rybelsus, Trulicity Saxenda, Victoza, Phentermine (Adipex, Lomaira), Extended-release Phentermine\u002FTopiramate (Qsymia), Extended-release Naltrexone\u002FBupropion (Contrave), Plenity, Orlistat (Xenical) or Other GLP-1 receptor agonist, or any other drug to treat obesity or there is less than 7 weeks since last dosage.\n* Has undergone weight loss\u002Fbariatric surgery or is planning to undergo such surgery in the next 12 months.","21 Years",{"count":416,"type":22},1785,[85],"The researchers will conduct 'Taxi ROADmAP (Realizing Optimization Around Diet And Physical activity)', which also utilizes MOST, and the same 4 obesity intervention components as in SANOS, but targets the overweight\u002Fobesity crisis in another at-risk, low socioeconomic status (SES) population, taxi and for-hire vehicle (FHV) drivers (Lyft, Uber, etc.). ROADMAP also utilizes an effectiveness- implementation hybrid type 1 design. Hybrid trials, which blend effectiveness and implementation studies, can lead to more rapid translational uptake and more effective implementation. Taxi and FHV drivers are a growing, multilingual, hard-to-reach, predominantly immigrant and minority essential worker population. There are over 750,000 licensed taxi and FHV drivers in in the U.S. and over 185,000 in New York City (NYC). They have higher rates of overweight\u002Fobese range body mass index (BMI) than New Yorkers in general (77% vs 56%) and have high rates of elevated waist circumference, sedentary behavior, poor diets, and health care services underutilization. ROADmAP will test 4 evidence- and theory-based (Social Cognitive Theory \\[SCT\\]) behavior change intervention components. We will use MOST to identify which of the 4 components contribute most significantly and cost-effectively to weight loss among NYC drivers recruited at workplace health fairs (HFs) and virtually. Objectives are to apply MOST to design an optimized version of a scalable, lifestyle intervention for taxi\u002FFHV drivers, and then to conduct a mixed methods multistakeholder process evaluation to facilitate widespread intervention implementation.",[88,420,29,89,365],"Overweight and Obesity",[422,88,420,29,89,365,423],"Focus Groups","Memorial Sloan Kettering Cancer Center","2026-01-23",{"date":426,"type":34},"2026-01-26",{"date":428,"type":34},"2022-12-22",{"date":430,"type":22},"2027-08-11",{"name":423,"class":72},{"id":433,"slug":434,"hasResults":12,"nctId":435,"briefTitle":436,"officialTitle":437,"acronym":4,"eligibilityCriteria":438,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":138,"enrollmentInfo":439,"targetDuration":4,"studyType":23,"phases":441,"briefSummary":442,"conditions":443,"keywords":4,"overallStatus":225,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":451,"locationsCount":453},"100614018","phase-3-a-phase-iii-study-to-evaluate-the-efficacy-and-safety-of-mdr-001-in-adult-participants-with-overweight-or-obesity-mobile-100614018","NCT07274137","A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE）","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of MDR-001 Administered Orally Over 52 Weeks in Participants With Overweight or Obesity (MOBILE)","Inclusion Criteria:\n\n* Have given written informed consent to participate in this study\n* Chinese male or female participants who are aged 18-65 (inclusive) years at the time of signing the ICF\n* Participants who are obesity (BMI ≥ 28.0 kg\u002Fm2), or overweight (24.0 kg\u002Fm2 ≤ BMI \\\u003C 28.0 kg\u002Fm2) with at least one of the the following weight-related comorbidities at screening:1) Pre-diabetes. 2) Hypertension.3) Dyslipidemia.4) Fatty liver.5) Obstructive sleep apnea syndrome.6) Complaint of weight-bearing joint pain.\n* Participants had a stable weight maintenance during the 3 months of dietary and physical activity prior to screening (participant-reported data acceptable) and no more than 5% weight fluctuation\n\nExclusion Criteria:\n\n* Obesity induced by secondary diseases or drug\n* Have diabetes mellitus\n* Have any lifetime history of a suicidal attempt or suicidal behavior\n* Have a history of depressive disorder\n* History of gout within 6 months prior to screening\n* History of major cardiovascular or cerebrovascular disease within 6 months prior to screening, defined as:1)Acute myocardial infarction (MI), percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), heart valve repair\u002Freplacement, unstable angina, hemorrhagic stroke (stroke), ischemic stroke (including transient ischemic attack \\[TIA\\]).2)Congestive heart failure of New York Heart Association (NYHA) class III or IV.3)Severe arrhythmias\n* History of malignancy within 5 years prior to screening or newly diagnosed malignancy at screening\n* Have a family or personal history (parents, children, and siblings of medullary thyroid cancer or Multiple Endocrine Neoplasia Syndrome Type 2 .\n* Abnormal thyroid function tests at screening not adequately controlled by stable medication doses , or thyroid ultrasound at screening showing thyroid nodules classified as Chinese-thyroid imaging-reporting and data system category 4 or higher.\n* History of significant gastrointestinal disease or gastrointestinal surgery or clinically significant gastric emptying abnormality within 6 months prior to screening.\n* History of intestinal disorders deemed clinically significant by the investigator, or acute hemorrhoidal episode within 3 months prior to screening.\n* History of acute or chronic pancreatitis, or abnormally elevated serum amylase or lipase levels at screening.\n* revious acute or chronic hepatitis, or symptoms and signs of any other liver disease other than non-alcoholic fatty liver disease, or abnormalities in related laboratory tests at screening\n* Presence of acute or chronic cholecystitis at screening, or symptomatic or treatment-requiring cholelithiasis\u002Fgallbladder polyps at screening, or newly diagnosed cholelithiasis within 6 months before screening\n* Hypersensitivity or suspected hypersensitivity to glucagon-like peptide 1 receptor agonist (GLP-1RA) drugs or excipients.\n* History of drug abuse or dependence prior to screening.\n* Have current or history of treatment with medications that may cause significant weight gain within 3 months prior to screening, including but not limited to:\n\n  1. Approved\u002Funapproved marketed weight-loss drugs: orlistat, sibutramine hydrochloride, phentermine, phentermine-topiramate, naltrexone-amfebutamone, tirzepatide, semaglutide, liraglutide, beinaglutide, phendimetrazine, methylamphetamine, etc.\n  2. Investigational products of weight-loss: Glucagon-like peptide 1 receptor (GLP-1R) agonists, GLP-1R\u002Fglucagon receptor (GCGR) agonists, glucose-dependent insulinotropic polypeptide receptor (GIPR)\u002FGLP-1R agonists, GIPR\u002FGLP-1R\u002FGCGR agonists,GLP-1R agonists\u002Factivin type II receptor (ActRII) inhibitors, GLP-1R\u002FGIPR\u002Ffibroblast growth factor 21 receptor (FGF21R) agonists or FGF21R\u002FGCGR\u002FGLP-1R agonists.\n  3. Hypoglycemic drugs, such as metformin, sodium-glucose cotransporter 2 (SGLT2) inhibitors, thiazolidinediones (TZDs) or dipeptidyl peptidase 4 (DPP-4) inhibitors.\n  4. Systemic steroid therapy (including intravenous, oral, intra-articular).\n  5. Tricyclic antidepressants or other antipsychotic or antiepileptic drugs affecting body weight (e.g., mirtazapine, paroxetine, clozapine, olanzapine, risperidone, quetiapine, paliperidone, valproic acid, valproic acid derivatives, lithium).\n* History of bariatric surgery (excluding acupuncture\u002Fcupping\u002Fcatgut embedding for bariatric surgery, liposuction, and abdominoplasty performed \\>1 year prior to screening) or plans to undergo bariatric surgery or acupuncture\u002Fcupping\u002Fcatgut embedding, liposuction, abdominoplasty during the study period.\n* Planned chronic use of medications affecting gastrointestinal motility or scheduled gastric emptying-impairing surgery during the study period.\n* Major or medium-sized surgery, or severe trauma or serious infection within 3 months prior to screening, which, as assessed by the investigator, would preclude trial participation, or planned surgery during the study period (excluding outpatient procedures deemed by the investigator to have no impact on subject safety or trial outcomes).\n* History of organ transplant.\n* Use of any drug or food known to potently or moderately inhibit or induce cytochrome P450 3A4 enzyme (CYP3A4) and\u002For inhibit P-glycoprotein (P-gp) within 28 days prior to the first dose and throughout the study.\n* Currently participating in any other clinical study, or if received any investigational product or medical devices within ≤ 3 months or 5 half-lives (t1\u002F2) prior to screening, whichever is longer.\n* Donation or loss of ≥ 400 mL of blood or transfusion\u002Fblood products during this period within 3 months prior to screening, or intention to donate blood during the study.\n* emale participants during pregnancy or lactation.\n* The investigator, site personnel, and\u002For their immediate family members directly related to the study. An immediate family member is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.\n* Participants who may be unable to complete this study for other reasons, or have other conditions that, as assessed by the investigator, will make the participant unsuitable for participation in this study, for example, the participant refuses to use only the weight-loss drugs specified in the protocol during the study.",{"count":440,"type":22},738,[25],"This is a multicenter, randomized, double-blind, placebo-controlled, phase III clinical study to evaluate the efficacy and safety of the oral small molecule MDR-001 Tablets over 52 weeks as an adjunct to a lifestyle intervention in participants with overweight or obesity.The goal of this clinical trial is to determine whether the oral drug MDR-001 can improve weight management in adult participants with overweight or obesity.",[29],"2025-12-15",{"date":446,"type":34},"2025-12-22",{"date":448,"type":22},"2026-02",{"date":450,"type":22},"2027-07",{"name":452,"class":41},"MindRank AI Ltd",45,{"id":455,"slug":456,"hasResults":12,"nctId":457,"briefTitle":458,"officialTitle":459,"acronym":4,"eligibilityCriteria":460,"healthyVolunteers":49,"sex":18,"minAge":19,"maxAge":461,"enrollmentInfo":462,"targetDuration":4,"studyType":23,"phases":464,"briefSummary":465,"conditions":466,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":468,"startDateStruct":470,"completionDateStruct":472,"leadSponsor":474,"locationsCount":73},"100615563","phase-1-a-study-of-bgm1812-injection-in-healthy-and-non-diabetic-overweight-or-obese-chinese-participants-100615563","NCT07294235","A Study of BGM1812 Injection in Healthy and Non-diabetic Overweight or Obese Chinese Participants","A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single\u002FMultiple-dose Study to Evaluate the Tolerability, Safety and Pharmacokinetics of BGM1812 in Healthy and Non-diabetic Overweight or Obese Chinese Participants","Inclusion Criteria:\n\n* Between the ages of 18 and 65 years (inclusive) at the time of screening , healthy and non-diabetic overweight or obese subjects , both male and female;\n* Healthy subjects , male weight ≥ 50 kg, female weight ≥ 45 kg, and body mass index (BMI): 20.0 kg\u002Fm² ≤ BMI \\\u003C 24 kg\u002Fm²（BMI = weight\u002Fheight²）;\n* Obese individuals: BMI ≥ 28.0 kg\u002Fm², or overweight individuals: 24.0 kg\u002Fm² ≤ BMI \\\u003C 28.0 kg\u002Fm²;\n* (Medical Inquiry) Have a stable body weight (\\\u003C5% self-reported change during the previous 12 weeks) before screening.\n* Have no history of mental disorders, be able to communicate smoothly with Investigator, Capable of understanding the written informed consent document; willingly provides valid, signed written informed consent; willing and able to comply with the schedule, requirements and restrictions of the study.\n* Male subjects with female partners of reproductive potential must agree to practice abstinence or to use a condom (male subject) plus an additional medically acceptable form of contraception (female partner) for the duration of the study and for at least 3 months after dosing; must also agree to refrain from sperm donation for at least 3 months post dose.\n\nExclusion Criteria:\n\n* Those with a history of severe drug allergies (especially those with known or suspected allergies to related compounds of BGM1812), or complicated with severe specific allergic diseases\u002Fhistory, or with a severe allergic constitution.\n* Subjects with positive results for HBsAg, anti-HCV, anti-HIV or anti-TP during the screening period.\n* 12-lead ECG shows ventricular heart rate \\\u003C 50 beats\u002Fmin or \\> 100 beats\u002Fmin at screening\u002Fbaseline, second or third degree atrioventricular block, long QT syndrome, QTcF\\> 470ms for women or \\> 450ms for men, pre-excitation syndrome or other significant arrhythmias.\n* Used illegal drugs within 6 months prior to screening, or substance abuse within 12 months prior to screening.\n* Participated in drug or medical device clinical trials and treated with Study Drug (excluding placebo) or medical device intervention within 12 weeks before screening.\n* Participants who have received any vaccine within 2 weeks prior to screening, or plan to receive a vaccine during the trial.\n* Female participants who are pregnant or lactating, or those with a positive pregnancy test result during the screening period.\n* Positive urine drug test or alcohol serum test result at screening or at baseline.\n* Has any other conditions or disorders deemed unsuitable for including in the study, in the opinion of the Investigator.","55 Years",{"count":463,"type":22},60,[142],"The purpose of this study is to evaluate the tolerability , safety and pharmacodynamics of BGM1812 administered subcutaneously in healthy and non-diabetic overweight or obese Chinese participants, and to investigate the pharmacokinetic profile of BGM1812 in the bloodstream.",[29],"2025-12-07",{"date":469,"type":34},"2025-12-19",{"date":471,"type":34},"2025-12-05",{"date":473,"type":22},"2026-03-02",{"name":475,"class":41},"BrightGene Bio-Medical Technology Co., Ltd.",{"id":477,"slug":478,"hasResults":12,"nctId":479,"briefTitle":480,"officialTitle":481,"acronym":4,"eligibilityCriteria":482,"healthyVolunteers":49,"sex":18,"minAge":19,"maxAge":307,"enrollmentInfo":483,"targetDuration":4,"studyType":23,"phases":485,"briefSummary":486,"conditions":487,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":495,"locationsCount":73},"100548876","craving-network-neurofeedback-100548876","NCT06426693","Craving Network Neurofeedback","Connectome-based Neurofeedback of the Craving Network to Reduce Food Cue Reactivity","Inclusion Criteria:\n\n* Ages 18 to 60 years\n* Body mass index \\>25 kg\u002Fm2\n* \\>2.37 Food Craving Inventory score\n\nExclusion Criteria:\n\n* Current or past 6 months use of anti-obesity medications\n* Weight-reduced state defined as \\>10% weight reduction in the past 6 months.\n* Nicotine use\n* Current diagnosis of neurological or psychiatric disorder\n* Obesity-related diseases such as type-2 diabetes\n* Contraindications to MRI\n* Baseline scanning with motion \\>0.15mm frame to frame displacement.",{"count":484,"type":22},50,[54],"This project tests whether individuals with overweight or obesity and high craving can learn to change their brain response to food cues using neurofeedback, to impact their craving and eating behavior.",[29],"2025-12-02",{"date":490,"type":34},"2025-12-03",{"date":492,"type":34},"2024-11-27",{"date":494,"type":22},"2027-03-31",{"name":71,"class":72},{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":4,"eligibilityCriteria":502,"healthyVolunteers":49,"sex":18,"minAge":19,"maxAge":307,"enrollmentInfo":503,"targetDuration":4,"studyType":23,"phases":504,"briefSummary":505,"conditions":506,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":507,"lastUpdatePostDateStruct":508,"startDateStruct":510,"completionDateStruct":512,"leadSponsor":514,"locationsCount":154},"100588197","phase-1-a-study-to-evaluate-mwn109-tablets-in-healthy-adult-participants-100588197","NCT06938269","A Study to Evaluate MWN109 Tablets in Healthy Adult Participants","A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MWN109 Tablets in Healthy Adult Participants","Inclusion Criteria:\n\n1. Males or females aged 18 to 60 years (inclusive) at the time of signing the informed consent (Caucasians should be no less than 80% since the implementation of Protocol Clarification Letter #2, dated 02 Sep 2025).\n2. \\[Part A: SAD\\] Body mass index (BMI) of 19.0 to 40.0 kg\u002Fm2 (inclusive) with body weight \\> 65.0 kg and \\\u003C130.0 kg. \\[Part B: MAD\\] BMI of 27.0 to 45.0 kg\u002Fm2 (inclusive) with body weight \\> 65.0 kg and \\\u003C130.0 kg.\n3. Stable body weight within 3 months before screening (defined as self-reported change \\\u003C 5%).\n4. Resting heart rate (supine) ≥ 45 bpm and ≤ 90 bpm with a single 12-lead ECG at Screening. If the heart rate is \\> 90 or \\\u003C 45 bpm, it is to be repeated 2 more times (separated by at least 2 min) and the average of the 3 heart rate values is to be used to determine the participant's eligibility.\n5. Females of childbearing potential and males who are not surgically sterile (\\>180 days since vasectomy with no viable sperm) will agree to use contraception from Screening until 4 months after the last administration, OR females of non-reproductive potential as defined below:\n\n   * Postmenopausal as defined as:\n\n     * No menses for at least 12 months; OR\n     * No menses for at least 12 months AND with a follicle-stimulating hormone level \\> 40 IU\u002FL or according to the definition of \"postmenopausal range\" for the laboratory involved; OR\n   * History of hysterectomy; OR\n   * History of bilateral oophorectomy\n6. Male participants must agree to refrain from sperm donation and females should refrain from ova donation from Screening until 4 months after the last administration.\n7. Willing to maintain current general diet and physical activity regimen, except for the physical activity in the 72 h before each blood sample collection for the clinical laboratory analysis, which should not be strenuous, and willing to be restrained from alcohol and smoking during the study period.\n8. Able to comprehend and willing to sign an informed consent form (ICF) and to abide by all study requirements and restrictions.\n\nExclusion Criteria:\n\n1. Significant history or clinical manifestation of any cardiovascular, metabolic, allergic, endocrine, renal, hepatic, gastrointestinal, hematological, pulmonary, respiratory, dermatological, neurological, gynecological, psychiatric disorders, as determined by the Principal Investigator (or delegate).\n2. Screening blood pressure in supine outside the ranges 90-159 mmHg systolic, 50-95 mmHg diastolic. If abnormal blood pressure is observed, the blood pressure is to be repeated 2 more times, and the average of the 3 blood pressure values is to be used to determine the participant eligibility.\n3. History of insulinoma, or has an event of blood glucose \\\u003C 2.8 mmol\u002FL within 1 year prior to Screening, or with ≥ 3 times of hypoglycemia symptoms within 3 months prior to Screening.\n4. History of febrile illness within 7 days prior to the first dose of IP or participants with evidence of active infection.\n5. Any of the following:\n\n   1. QTcF \\> 450 msec confirmed by repeat measurement;\n   2. QRS duration \\> 120 msec confirmed by repeat measurement;\n   3. PR interval \\> 220 msec confirmed by repeat measurement. Notes: Regarding a), b) and c), ECG is to be repeated 2 more times when out-of-range and the average of the values is to be used to determine the participant eligibility;\n   4. Findings which would make QTc measurements difficult or QTc data uninterpretable;\n   5. History of additional risk factors for torsades de pointes (e.g., heart failure, hypokalemia, family history of long QT syndrome).\n6. Known history or family history of thyroid C-cell tumor\u002Fcarcinoma, multiple endocrine neoplasia syndrome type 2 (MEN2), thyroid dysfunction or thyroid hormone abnormality.\n7. History of diabetes mellitus or clinical evidence of diabetes (e.g., hemoglobin A1c ≥ 6.5%, fasting plasma glucose ≥ 126 mg\u002FdL \\[7.0 mmol\u002FL\\]) at Screening, non-fasting plasma glucose ≥ 200 mg\u002FdL (11.1 mmol\u002FL) at Screening, or use of any hypoglycemic drugs during Screening or within 3 months prior to Screening.\n8. History of acute or chronic pancreatitis, symptomatic gallbladder disease, pancreatic injury and other high-risk factors that may lead to pancreatitis.\n9. With any of following laboratory abnormality at screening and confirmed by a single repeat at the discretion of the Principal Investigator (or delegate):\n\n   a) Elevation in serum amylase or lipase (\\> 1.5 × upper limit of normal \\[ULN\\]). b) Have serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\> 1.5 × ULN or total bilirubin \\>1.5 × ULN.\n\n   c) Have serum triglycerides (TG) ≥ 5.65 mmol\u002FL (500 mg\u002FdL) at Screening. d) Estimated glomerular filtration rate (eGFR) \\\u003C 80 mL\u002Fmin\u002F1.73m2 by Cockcroft-Gault equation as below: (140 - age) × mass (kg)\u002F72 × creatinine (mg\u002FdL); multiply by 0.85 if female.\n10. Untreated or uncontrolled hypothyroidism\u002Fhyperthyroidism defined as thyroid-stimulating hormone \\> 6 mIU\u002FL or \\\u003C 0.4 mIU\u002FL.\n11. History of clinically significant (in the opinion of the Principal Investigator or delegate) abnormal gastric emptying (e.g., gastric outlet obstruction, gastroparesis), chronic gastrointestinal diseases (e.g., having active ulcer within 6 months prior to Screening, active gastritis or esophagitis, or gastroesophageal reflux disease, irritable bowel disease or severe inflammatory bowel disease).\n12. Presence of clinically significant acute gastrointestinal symptoms (e.g., nausea, vomiting, heartburn or diarrhoea) or malabsorptive states (celiac disease, lactose intolerance or chronic pancreatitis), as judged by the Principal Investigator (or delegate).\n13. Any history or plan of gastrointestinal surgery excluding appendectomy.\n14. Positive hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV-Ab), or human immunodeficiency virus (HIV-1 and HIV-2) antibodies.\n15. Any history of severe psychiatric disorder such as major depressive disorder, bipolar disorder, and schizophrenia, or history of suicidal ideation, behavior or attempts or other psychiatric disorder.\n16. History of alcoholism or drug\u002Fchemical abuse within 1 year prior to D-1.\n17. Alcohol consumption of \\> 21 units per week for males and \\> 14 units per week for females, on average. One unit of alcohol equals 1\u002F2 pint (285 mL) of beer, 1 glass (125 mL) of wine, or 1\u002F6 gill (25 mL) of spirits.\n18. Positive alcohol breath test result or positive urine drug screen (confirmed by repeat) during the Screening period.\n19. Daily use of more than 10 cigarettes\u002Fday (on average), or 2 cigars\u002Fday (on average), or equivalent use of any nicotine-containing product within 6 weeks prior to Screening.\n20. Participant is unwilling to refrain from strenuous exercise (e.g., heavy lifting, weight training, and aerobics) for 72 h prior to each blood collection for clinical laboratory tests.\n21. Females of pregnant or lactating, or those with a positive pregnancy test at Screening.\n22. Intolerance to venipuncture for blood sampling or history of fainting at blood drawing or sight of blood, unless deemed acceptable by the Principal Investigator (or delegate).\n23. Long-term use of drugs directly affecting the gastrointestinal motility (including but not limited to mosapride, cisapride) or gastrointestinal surgery within 12 weeks prior to Screening and are inappropriate for participation in this clinical study as assessed by the Principal Investigator (or delegate).\n24. History of severe Types I-IV hypersensitivity reactions, anaphylaxis, cytokine release syndrome, atopic individuals, or allergic reactions to multiple drugs. If the Principal Investigator (or delegate) is considering enrolling a participant with multiple drug allergies, agreement with the Medical Monitor should be sought.\n25. History of or suspected allergy or hypersensitivity to the IP or its components.\n26. Use or intend to use any prescription medications\u002Fproducts other than hormone replacement therapy, oral, implantable, transdermal, injectable, or intrauterine contraceptives within 14 days prior to dosing, unless deemed acceptable by the Principal Investigator (or delegate)and agreement with the Sponsor.\n27. Use or intend to use slow-release medications\u002Fproducts considered to still be active within 14 days prior to D-1, unless deemed acceptable by the Principal Investigator (or delegate).\n28. Use of any nonprescription medications\u002Fproducts including vitamins, minerals, and phytotherapeutic\u002Fherbal\u002Fplant-derived preparations within 7 days prior to D-1 or during the study, unless deemed acceptable by the Principal Investigator (or delegate) and agreement with Sponsor, with the exception of paracetamol\u002Facetaminophen (maximum 2 g per day for up to 3 days) and topically applied medications which is permitted up to 48 h prior to dosing.\n29. Participants with a history of infectious diseases (which may affect the ability of the participant to participate in the study at the discretion of the Principal Investigator or delegate), severe trauma, or major surgical operation within 4 weeks prior to Screening.\n30. Have been vaccinated within 4 weeks prior to Screening or plan to have vaccination during the study.\n31. Donation of blood or massive blood loss (\\> 450 mL) OR receipt of blood products within 12 weeks prior to Screening, plasma from 2 weeks prior to Screening, and platelets from 6 weeks prior to Screening.\n32. Participation in a clinical study involving administration of an investigational agent\u002Fdevice or vaccine (new chemical entity) within 30 days or 5 half-lives, or having received a biological product within 12 weeks prior to Screening.\n33. Poor peripheral venous access.\n34. Are investigative site personnel directly affiliated with this study and their immediate families. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.\n35. The presence of clinically significant physical examination, vital sign, drug, or ECG findings at Screening or baseline or laboratory findings at Screening that, in the opinion of the Principal Investigator (or delegate) or Medical Monitor, may interfere with any aspect of study conduct or interpretation of results.\n36. Are deemed unsuitable by the Principal Investigator (or delegate) for any other reason.",{"count":463,"type":22},[142],"This is a Phase 1, randomized, double-blind, placebo-controlled, single-and-multiple ascending dose study in which the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of orally administered MWN109 tablets will be assessed in healthy adult participants.",[29],"2025-11-17",{"date":509,"type":34},"2025-11-20",{"date":511,"type":34},"2025-06-18",{"date":513,"type":22},"2026-05",{"name":515,"class":41},"Shanghai Minwei Biotechnology Co., Ltd",{"id":517,"slug":518,"hasResults":12,"nctId":519,"briefTitle":520,"officialTitle":521,"acronym":4,"eligibilityCriteria":522,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":461,"enrollmentInfo":523,"targetDuration":4,"studyType":23,"phases":525,"briefSummary":526,"conditions":527,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":529,"startDateStruct":530,"completionDateStruct":532,"leadSponsor":534,"locationsCount":73},"100604549","phase-1-relative-bioavailability-of-first-vs-second-generation-formulations-of-hrs9531-tablets-in-obese-or-overweight-subjects-100604549","NCT07150962","Relative Bioavailability of First vs Second-Generation Formulations of HRS9531 Tablets in Obese or Overweight Subjects","A Phase I Clinical Study Comparing the Relative Bioavailability, Safety and Tolerability of the First-generation and Second-generation Formulations of HRS9531 Tablets and Exploring the Safety, Tolerability and Pharmacokinetic Characteristics of Single-dose Escalation of the Second-generation Formulation","Inclusion Criteria:\n\n1. Ability to understand the trial procedures and possible adverse events, be able and willing to provide a written informed consent;\n2. Male subjects aged 18-55 years on the date of signing informed consent (inclusive);\n3. Body weight ≥65 kg, body mass index (BMI) within the range of 24.0-35.0 kg\u002Fm2 (inclusive);\n4. The weight change within the previous 3 months should not exceed 5 kilograms.\n5. Based on the patient's past medical history, physical examination, vital signs, laboratory tests and electrocardiogram (ECG) examinations, the researchers determined that the overall overweight and obese subjects were included.\n\nExclusion Criteria:\n\n1. Those who are known or suspected to be allergic to any component of the investigational drug or related products; or those who have a history of multiple or severe allergies to drugs or foods, or a history of severe immediate allergic reactions;\n2. Chronic or severe medical history of the respiratory system, circulatory system, digestive system, urinary system, blood system, endocrine system, immune system, nervous system, mental system, etc., or those with existing systemic diseases mentioned above, and judged by the investigator to be unsuitable to participate in this study;\n3. Having a history of hypertension or when the researchers determine during the screening that the blood pressure is abnormal and has clinical significance;\n4. Those with a history of obvious gastrointestinal diseases or related symptoms (such as nausea, vomiting, heartburn sensation or diarrhea), conditions that affect gastric emptying (such as pyloric stenosis), or who have undergone any gastrointestinal surgery (such as weight loss surgery; except for intestinal polyp resection and appendectomy), or who had acute diarrhea within the previous 7 days; diarrhea is defined as watery stools and\u002For more than 3 bowel movements per day;\n5. Participation in clinical trials of any drug or medical device in the 3 months or 5 half-lives, whichever longer, prior to dosing;\n6. Blood donation history or blood loss ≥400 mL within 3 months or ≥200 mL within 1 month before dosing, or received blood transfusion within 3 months before dosing;\n7. Hepatitis B surface antigen (HBsAg), HIV antibody, hepatitis C virus antibody (HCVAb), treponema pallidum specific antibody detection, positive;\n8. Those who have a history of drug abuse or drug use, or who have a positive result in the urine drug screening test during the screening period;\n9. Heavy drinkers (average weekly alcohol consumption of ≥ 14 units in the six months prior to screening: 1 unit of beer = 285 mL, or spirits = 25 mL, or wine = 100 mL; average daily smoking ≥ 5 cigarettes); those unable to quit smoking and drinking during the trial; those with positive alcohol blood tests.",{"count":524,"type":22},168,[142],"This study aims to compare the relative bioavailability, safety and tolerability of the first-generation and second-generation formulations of HRS9531 tablets, as well as to explore the safety, tolerability and pharmacokinetic characteristics of the second-generation formulation in terms of single-dose escalation.",[29],"2025-11-14",{"date":507,"type":34},{"date":531,"type":34},"2025-10-15",{"date":533,"type":22},"2026-09",{"name":535,"class":41},"Fujian Shengdi Pharmaceutical Co., Ltd.",{"id":537,"slug":538,"hasResults":12,"nctId":539,"briefTitle":540,"officialTitle":540,"acronym":541,"eligibilityCriteria":542,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":184,"enrollmentInfo":543,"targetDuration":4,"studyType":23,"phases":544,"briefSummary":545,"conditions":546,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":548,"lastUpdatePostDateStruct":549,"startDateStruct":550,"completionDateStruct":552,"leadSponsor":554,"locationsCount":154},"100554497","phase-3-semaglutide-for-metabolic-intervention-and-adipose-loss-to-treat-atrial-fibrillation-100554497","NCT06499857","Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation","SEMINAL-AF","Inclusion Criteria:\n\n1. Age 18-75 years\n2. BMI greater than or equal to 30 kg\u002Fm2\n3. Paroxysmal AF or persistent AF, in whom catheter ablation (CA) for AF is expected within 1 year (A group) or in whom catheter ablation is NOT expected within 1 year (M group)\n4. Ability to provide informed consent before any trial-related activities.\n5. Patients with type 2 diabetes mellitus (T2DM) will be included:\n\n   1. If HbA1c (glycated hemoglobin) is less than or equal to 10 %\n   2. If the subject is taking basal insulin only or oral hypoglycemic agents or a combination of those.\n   3. Patients on SGLT2-inhibitors and TZDs (Thiazolidinedione) will be included if they have been on a stable dose of these medications for at least 6 months\n   4. The following protocol will be adopted to adjust insulin secretagogues (sulfonylureas or meglitinides) and insulin during the study (adapted from the Look Ahead Study).\n\nPatients will be asked to check their blood glucose (BG) 4 x day (before meals and at bed time) during the dose escalation and dose stabilization phases (weeks 0 to 20) and recommendation of dose adjustments will be immediately sent to their treating physician according to the dose adjustment scale below:\n\n* 2 blood sugars \\\u003C100 mg\u002Fdl- reduce meds \\[insulin secretagogues (sulfonylureas or meglitinides) and basal insulin\\] by 0-50 %\n* 3 blood sugars 80-100 mg\u002Fdl- reduce meds \\[insulin secretagogues (sulfonylureas or meglitinides) and basal insulin\\] by 25-75%\n* 3 blood sugars \\\u003C80 mg\u002Fdl \\> 2 x week or severe hypoglycemia or symptomatic hypoglycemia- reduce meds \\[insulin secretagogues (sulfonylureas or meglitinides) and basal insulin\\] by 50-100 %\n\nRandomization to treatment (active and placebo) will be stratified to balance patients with T2DM across the study arms. After completion of the trial a prespecified subgroup analysis of the patients enrolled affected by T2DM will be performed.\n\nFor women of child-bearing potential, use of appropriate contraception will be required.\n\nIn patients that are prescribed amiodarone, standard care practices will be implemented to evaluate for liver and thyroid side effects with baseline liver and thyroid function tests via blood draw and evaluation every 6 months.\n\nExclusion Criteria:\n\n1. Current use of GLP-1 RA (glucagon-like peptide receptor agonists) or DPP4 (Dipeptidyl peptidase-4)-inhibitors or use within the last 90 days prior to screening\n2. Current antiobesity medication use or use within the last 90 days prior to screening\n3. A self-reported change in body weight of \\> 5 kg (11 lb.) within 30 days before screening\n4. History of bariatric surgery\n5. History of type I diabetes mellitus\n6. Current use of prandial insulin\n7. Hospitalization for unstable angina, or TIA (Transient ischemic attack) \\\u003C 30 days prior to screening\n8. Pulmonary embolism \\\u003C 90 days before screening\n9. MI (myocardial infarction), stroke, etc. \\\u003C 90 months prior to screening\n10. Uncontrolled thyroid disease: TSH (Thyroid-stimulating hormone) \\> 10.0 mIU\u002FL (Milli-international Units Per Liter) or \\\u003C 0.4 mIU\u002FL (Milli-international Units Per Liter) at screening\n11. Active malignancy\n12. Active enrollment in another investigational study that includes any kind of intervention\n13. The receipt of any investigational drug within 90 days prior to this trial.\n14. Inability to comply with study procedures\n15. Acute pancreatitis \\\u003C 180 days before screening\n16. History or presence of chronic pancreatitis\n17. CKD (Chronic Kidney Disease) stage 4 (GFR \\\u003C30 ml\u002Fmin)\n18. A personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)\n19. A prior serious hypersensitivity reaction to semaglutide or to any of the excipients in WEGOVY\n20. Chronic inflammatory conditions requiring immunosuppression and\u002For on glucocorticoids\n21. Previous participation in this trial (received at least one dose of study drug or placebo)\n22. Pregnant, breast-feeding or planning pregnancy",{"count":117,"type":22},[25],"The goal of the study is to learn how a weight loss medication called semaglutide, which is used to treat obesity, in addition to standard AF treatment might affect AF, atrial fibrillation severity, and whether it changes the risk of atrial fibrillation recurring after standard AF treatments.",[29,547],"Atrial Fibrillation","2025-11-13",{"date":528,"type":34},{"date":551,"type":34},"2025-04-14",{"date":553,"type":22},"2028-06",{"name":555,"class":72},"University of Chicago",{"id":557,"slug":558,"hasResults":12,"nctId":559,"briefTitle":560,"officialTitle":561,"acronym":4,"eligibilityCriteria":562,"healthyVolunteers":49,"sex":18,"minAge":19,"maxAge":461,"enrollmentInfo":563,"targetDuration":4,"studyType":23,"phases":564,"briefSummary":565,"conditions":566,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":568,"lastUpdatePostDateStruct":569,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":575,"locationsCount":73},"100610193","phase-1-evaluate-the-pharmacokinetics-pharmacodynamics-safety-and-tolerability-of-bgm1812-injection-following-single-and-multiple-subcutaneous-administration-in-normal-to-overweight-or-obese-but-otherwise-healthy-men-and-women-100610193","NCT07224399","Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multiple Subcutaneous Administration in Normal to Overweight or Obese But Otherwise Healthy Men and Women","A Phase 1, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multiple Subcutaneous Administration in Normal to Overweight or Obese But Otherwise Healthy Men and Women","Inclusion Criteria:\n\n* Capable of understanding the written informed consent document; willingly provides valid, signed written informed consent; willing and able to comply with the schedule, requirements and restrictions of the study.\n* Body mass index (BMI) meeting one of the following requirements:\n\n  1. Between ≥ 30.0 kg\u002Fm2 and ≤ 40.0 kg\u002Fm2 (obese) (for Cohort 3-6); OR\n  2. Between ≥ 27.0 kg\u002Fm2 and \\\u003C 30.0 kg\u002Fm2 (overweight) with at least 1 of the following: One or more symptoms of prediabetes (impaired fasting plasma glucose and\u002For abnormal glucose tolerance), grade 1 hypertension, simple fatty liver or dyslipidemia (For Cohort 3- 6); OR\n  3. Between ≥ 23.0 kg\u002Fm2 and \\\u003C 27.0 kg\u002Fm2 healthy subjects (for Cohort 1 and Cohort 2)\n* Have a stable body weight (\\\u003C5% self-reported change during the previous 12 weeks) before screening\n\nExclusion Criteria:\n\n* Have allergic predisposition (allergic to 3 or more foods or drugs), or are allergic to amylin agonist-based therapeutic agents or suffer from severe allergic diseases (asthma, urticaria, eczematous dermatitis).\n* Known type I\u002FII diabetes.\n* Has underwent gastric bariatric surgery in the past, or has had liposuction or fat removal within 1 year before screening, or plan to have bariatric surgery, liposuction or abdominal fat removal during the study period or other surgery that would obviously affect the body weight.\n* History of acute or chronic pancreatitis or pancreatic injury.\n* Has any other conditions or disorders deemed unsuitable for including in the study, in the opinion of the Investigator.",{"count":463,"type":22},[142],"This is a Phase 1, single-center, double-blind, placebo-controlled, dose-escalation study. The study will evaluate the pharmacokinetics (PK), pharmacodynamic (PD), preliminary efficacy, safety and tolerability of BGM1812 following single and multiple SC administrations in normal to overweight or obese but otherwise healthy subjects.",[567,29],"Healhty","2025-11-05",{"date":570,"type":34},"2025-11-06",{"date":572,"type":34},"2025-10-09",{"date":574,"type":22},"2026-05-15",{"name":475,"class":41},{"id":577,"slug":578,"hasResults":12,"nctId":579,"briefTitle":580,"officialTitle":581,"acronym":4,"eligibilityCriteria":582,"healthyVolunteers":49,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":583,"targetDuration":4,"studyType":585,"phases":4,"briefSummary":586,"conditions":587,"keywords":590,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":594,"lastUpdatePostDateStruct":595,"startDateStruct":597,"completionDateStruct":599,"leadSponsor":601,"locationsCount":73},"100596370","emotion-examining-implicit-attitudes-in-physical-activity-engagement-100596370","NCT07044570","eMOTION: Examining Implicit Attitudes in Physical Activity Engagement","Using Real-Time Data Capture to Examine Implicit Attitudes as Mediators of Physical Activity Adherence in Interventions","Inclusion Criteria:\n\n1. Aged ≥ 18 years\n2. Reside in the United States\n3. Self-reported BMI ≥ 25\n4. Current structured physical activity engagement \\\u003C 60 minutes per week\n5. Own a personal smartphone device\n6. Reside in an area with Internet or Wi-Fi connectivity during the study period\n7. Able to speak and read in English\n8. Interested and willing to start a physical activity program\n9. Willing to wear a Fitbit Versa smartwatch provided by the study team everyday continuously (including at work and during physical activity), in place of any Fitbits or smartwatches previously worn, for the duration of the study period\n10. Able to read the small font on a smartwatch screen without glasses, or willing to carry reading glasses during physical activity for the purpose of reading the smartwatch screen\n11. Enrolled in the parent eMOTION intervention study\n\nExclusion Criteria:\n\n1. Inability to provide informed consent due to cognitive disability\n2. Inability to engage in one or more key treatment components, including those with medical conditions that preclude physical activity engagement or who cannot wear an accelerometer on the wrist or answer brief surveys on the smartwatch for any reason\n3. Current pregnancy\n4. Referred to the study by another participant or from Reddit.",{"count":584,"type":22},120,"OBSERVATIONAL","This early-phase trial will test intervention strategies to influence implicit attitudes towards physical activity and determine whether changes in those mechanisms result in change in physical activity behavior among inactive adults who are overweight or obese.",[588,29,589],"Physical Activity","Cancer",[591,592,588,593],"Affective Response","Psychological Needs","Implicit Attitudes","2025-10-30",{"date":596,"type":34},"2025-11-03",{"date":598,"type":34},"2025-03-24",{"date":600,"type":22},"2026-06-30",{"name":602,"class":72},"University of Southern California",{"id":604,"slug":605,"hasResults":12,"nctId":606,"briefTitle":607,"officialTitle":608,"acronym":4,"eligibilityCriteria":609,"healthyVolunteers":49,"sex":610,"minAge":19,"maxAge":461,"enrollmentInfo":611,"targetDuration":4,"studyType":23,"phases":613,"briefSummary":614,"conditions":615,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":616,"lastUpdatePostDateStruct":617,"startDateStruct":619,"completionDateStruct":621,"leadSponsor":623,"locationsCount":73},"100558181","phase-1-a-study-to-evaluate-features-of-kn069-in-participants-with-obesity-or-overweight-100558181","NCT06547775","A Study to Evaluate Features of KN069 in Participants With Obesity or Overweight","A Randomized, Double-blind and Placebo-controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN069 in Chinese Male Participants With Obesity or Overweight","Inclusion Criteria:\n\n1. Male, 18-55 years old (including threshold);\n2. Body mass index (BMI)：24.0 kg\u002Fm2≤BMI\\\u003C35 kg\u002Fm2；\n3. HbA1c\\\u003C6.5%；3.9mmol\u002FL≤Fasting blood glucose level \\\u003C7.0mmol\u002FL；\n4. Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures and are willing to follow study restrictions; Are able and willing to sign the ICF.\n\nExclusion Criteria:\n\n1. Those who have a history of chronic diseases or are currently suffering from obvious systemic diseases, such as diseases of cardiovascular system, respiratory system, endocrine and metabolic system, urinary system, digestive system, blood system, autoimmune system, neurological or psychiatric system, bacterial or viral infection;\n2. History of acute or chronic pancreatitis; A personal or family history of medullary thyroid cancer or multiple endocrine adenoma syndrome type 2; A history of other malignancies;\n3. History of GI disorder (for example, relevant esophageal reflux or gall bladder disease) or any GI disease which impacts gastric emptying (for example, gastric bypass surgery, pyloric stenosis, with the exception of appendectomy) or could be aggravated by GLP-1 analogs or DPP-IV inhibitors;\n4. Participants had cholecystolithiasis (removal of gallstones) or cholecystectomy (removal of gall bladder) in the past;\n5. Allergies to KN069 excipients or drugs similar to KN069 in structure or KN069 in the same category;\n6. A history of medicine abuse\u002Fdependence or narcotics abuse within 1 year prior to the screening and\u002For show positive findings on urinary drug screening;\n7. Have undergone any major surgery or surgery affecting drug absorption, distribution, metabolism, excretion within the 3 months prior to screening, or are scheduled to undergo surgery during the trial period (major surgery is defined as surgery on the intracranial, chest, abdomen, pelvic, or limb organs that result in major tissue trauma and require long-term recovery).\n8. Drinking more than 14 units of alcohol per week (1 unit =360ml beer or 45ml liquor with 40% alcohol or 150ml wine) in the 3 months before or during the screening period, alcohol cannot be banned during the hospital stay, and alcohol consumption cannot be limited to less than 2 units of alcohol per day during the post-discharge visit.\n9. Blood donation or blood loss ≥ 300 mL within 3 months prior to screening, or blood\u002Fblood components donation planned during the trial or within 1 month after the final study visit.\n10. Received administration of other drugs\u002Fvaccines in clinical trials within 2 months prior to screening; In other clinical trials at the time of screening;\n11. People who diet or undergo weight loss treatment within 2 months (for whatever reason) before administration, or who have made significant changes in their lifestyle habits.;\n12. Received vaccination within 14 days prior to screening, or have vaccination schedule during the trial, including inactivated vaccine, live attenuated vaccine, recombinant protein vaccine, recombinant adenovirus vaccine, RNA vaccine, DNA vaccine, COVID-19 vaccine;\n13. Use medication (including prescription drugs, over-the-counter drugs, herbal medicine) with the exception of vitamin\u002Fmineral supplements, paracetamol, topical medication, and contraceptives within 14 days prior to dosing.\n14. Use of GLP-1 analogues, GLP-1 receptor agonists, or any other formulations related to incretin and other drugs that the investigator believes may affect the trial within the 3 months prior to administration.\n15. Any abnormal patients who met the following criteria during screening: 1) serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) exceeded the upper limit of the reference value range by 2 times; Serum total bilirubin (TBIl) exceeded 1.5 times the upper limit of the reference value range; 2) Fasting triglyceride (TG) ≥5.6mmol\u002FL; 3) Physical examination, vital signs, electrocardiogram, laboratory examination, imaging and other abnormalities have clinical significance, and the investigator judges that they may pose a major risk to the subjects or interfere with the evaluation of safety, PK or PD results and are not suitable to participate in the trial;\n16. Positive breath test for alcohol (\\>0 mg\u002F100 mL);\n17. Evidence of hepatitis B\u002Fhepatitis C\u002FHIV\u002Fsyphilis.\n18. Urine screen positive for drug abuse.\n19. Participants that refuse to stay abstinent, and refuse to consistently use a form of highly effective birth control method starting at Screening (signing the ICF) and continuing throughout the clinical study period, and to 3 months after administration of IP; or to have a birth plan during the screening period until 3 months after dosing;\n20. Participants that plan to donate sperms from dosing until 3 months after administration of IP.\n21. Due to trauma, surgery, allergies or skin lesions, the abdominal skin is not suitable for subcutaneous injection.\n22. Other factors that the investigator considers unacceptable for participation in the study.","MALE",{"count":612,"type":22},36,[142],"This is a Phase 1, First-in-human, double-blinded, placebo-controlled study which aims to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the immunogenicity of KN069 in Chinese male participants with Obesity or Overweight.",[29],"2025-09-16",{"date":618,"type":34},"2025-09-17",{"date":620,"type":34},"2024-08-02",{"date":622,"type":22},"2027-06-30",{"name":624,"class":41},"Suzhou Alphamab Co., Ltd."]